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ABSTRACT
Neuron development involves intricate morphological changes reliant on
the serine/threonine kinase mammalian target of rapamycin complex 1 (mTORC1),
a cell growth regulator that supports anabolic processes such as mRNA
translation. Upregulated mTORC1 activity during neuron development causes
altered neuron morphology, which is a hallmark of neurodevelopmental disorders
such as Tuberous Sclerosis Complex (TSC). While the role of mTORC1 in neuron
development is well documented, there is insufficient information on what precise
upstream and downstream components of the mTOR pathway are involved.
Two underexplored regulators of neuron development are the unc-51 like
autophagy activating kinase 1 (Ulk1) and solute carrier family 7 member 5
(Slc7a5). Ulk1 is a pro-autophagic kinase and direct substrate of mTORC1.
Autophagy is important to general cell maintenance and is linked to synaptic
refinement via dendritic spine pruning. Ulk1 non-canonical functions involve GolgiEndoplasmic Reticulum trafficking, which is also vital for neuron development and
function. Slc7a5 is an amino acid transporter and upstream driver of mTORC1
activity by signaling the mTOR complex to the lysosomal surface for activation
when amino acids are present.
Herein, the role of mTORC1, Slc7a5, and Ulk1 is explored in mouse neuron
development, and we apply this insight to develop and propagate a neural stem
cell conditional Tsc2 knockout mouse colony. We demonstrate through genetic
manipulation that Ulk1 and Slc7a5 play a role in neuron development in vivo.
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Overexpression of Ulk1 in developing cortical neurons resulted in decreased
dendrite complexity. Increased Ulk1 Serine 757 phosphorylation in Ulk1
overexpressing neurons was associated with dendrite complexity closer to control
levels. Thus, mTORC1 mediated Ulk1 Serine 757 phosphorylation is likely required
during neuron development to control Ulk1 activity.
Slc7a5 knockdown was detrimental to olfactory bulb granule cell
development, specifically at later stages between Postnatal day 14-30. This is a
time of synaptic integration and continued growth of dendrites in granule cells.
Slc7a5 also regulates mTORC1 activity in granule cells during development.
Knockdown of Slc7a5 decreased mTORC1 activity as indicated by Ribosomal S6
phosphorylation. Decreased dendrite complexity following Slc7a5 knockdown was
partially rescued by Ras homolog enriched in brain (Rheb) overexpression, which
drives mTORC1 activity.
Finally, we documented defects in a Tsc2 transgenic mouse model and
documented developmental defects in Tsc2 null granule cells including dendrite
hypertrophy and increased soma size. Taken together, the presented research
demonstrates how neuron development is tightly regulated, with implications for
potential alternative therapeutic avenues in patients with altered mTOR activity in
the brain.
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CHAPTER I
Rationale for the Study of Neuron Development Regulators

A version of this data is published in Neuroscience Letters:
Sokolov, A. M., Seluzicki, C. M., Morton, M. C., Feliciano, D.M (2018) Dendrite
growth and the effect of ectopic Rheb expression on cortical neurons. Neurosci.
Lett.

Experiments presented in chapter I were conducted with Dr. David M. Feliciano,
Caitlyn M. Seluzicki, and Dr. Mary Morton.
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General Introduction.
The purpose of the studies presented here are to gain novel insight into
regulators of canonical neuron development using genetic in vivo manipulations
and applying this insight into the development of a Tuberous Sclerosis Complex 2
(Tsc2) mouse model. Undercovering the inner workings of the nervous system is
an arduous task that has only intensified with advances in technology. Humans
owe the evolution of the brain to our success as a species (1,2). On an individual
level, proper brain functionality allows for intricate levels of communication and
collaboration.
The importance of the brain means that proper development is critical to
quality of life. Many different aspects of brain development can go wrong and result
in debilitating neurological conditions such as epilepsy and intellectual disabilities.
This highlights the complexity of brain development and function, which is
dependent on the orchestration and fine-tuned interactions of many different cells.
The brain is made up of many different cell types, each being critical to
overall brain functionality. These cell types include neurons, astrocytes, microglia,
and oligodendrocytes. Additionally, each cell type falls under many different
subtypes. Each cell type has a unique critical role, but the true workhorse of the
brain directly responsible for brain function are neurons. Neurons form the network
in which the brain can carry out its function. This network is reliant on processes
called dendrites and axons that grow during development and form connections
with other neurons called synapses (3). Depending on the type of neuron, a
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chemical messenger called a neurotransmitter is released at one neuron
(presynaptic neuron) and exerts either an excitatory or inhibitory effect on the
receiving neuron (postsynaptic neuron) (3). Neurons can be connected to over
10,000 other neurons, and the sum of the receiving signals will cause a neuron to
fire an action potential if the neuron passes a depolarization threshold (4). Action
potentials are the mechanism in which neurons communicate within the neural
network (4).
Action potentials rely on ion gradients, where the neuron’s membrane
potential is negative at rest. A stimulus, such as the excitatory neurotransmitter
glutamate, is released by a presynaptic neuron and causes a flux of positive ions
into the postsynaptic neuron (4). If the membrane potential crosses a certain
threshold, the neuron will fire its own action potential in the form of a wave of
positive ions that travel down the axon (or dendrite in some cases). The action
potential invades and depolarizes the neuron’s presynaptic terminal, which results
in the release of neurotransmitters that influences the activation of other neurons
(5). These neurotransmitters are released and bind to receptors located on post
synaptic neuron dendritic spines (5). Many neurodevelopmental disorders are
caused by defective neuron development. Neurological defects can result from
issues such as altered neuron morphology, signaling changes, and ectopic
migration (6,7). For this reason, the continued investigation of neuron development
is paramount to address patient needs.
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Overview of Cortical Neuron Development.
Cortical neurogenesis involves arguably the most precise and intricate cell
migration events in the body (2). Neural stem cells (NSCs) in the ventricular zone
(VZ) comprise a neurogenetic niche that give rise to radial glial cells which further
produce cortical progenitors or postmitotic neurons that then migrate and form the
six layers of the cerebral cortex in an inside out position specific fashion, such that
deeper layer cells are older than the cells that make up the more superficial layers
(8–12). Cell migration is guided by glial shafts that provide a scaffold (13).
Following arrival to the terminal position, the cells mature into various types
of neurons. The cerebral cortex contains a vast amount of cellular heterogeneity,
with many classification schemes existing to classify neurons (14–16). One type is
the pyramidal neuron, which is the most abundant type in the cerebral cortex.
Pyramidal neurons have a soma, two dendrite domains, and a projecting axon that
extends to the ipsilateral or contralateral hemisphere (17–19). The two dendrite
domains are the apical dendrite, which extends toward the pial surface, and basal
dendrites that form more local connections. For example, basal dendrites of layer
II/III pyramidal neurons in mice typically do not extend past layer II/III, but can reach
layer IV when the neuron is situated in deeper regions of layer III (18). During
neuron development both dendrite types undergo extensive outgrowth and form
connections via synapses that integrate the neuron into the cortical network (20–
22).
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Neuron to neuron communication is a highly specialized process, with
neurons typically forming thousands of synapses with other neurons. Pyramidal
neurons are excitatory and receive glutamatergic input from their dendrites by
other pyramidal neurons while being kept in check via local GABAergic inhibitory
interneuron connections usually formed at the soma and axon (19,21). The
synaptic input field of neurons is thus in part determined by the localization of the
dendrites (21). Due to the postmitotic nature of pyramidal neurons in the cortex,
particularly in regard to higher functioning organisms such as humans, proper
morphogenesis during development is critical for proper neuron integration and
subsequent function (6,23–28). Dendrite structure has influence on neuron activity
including firing properties (24). Additionally, the size of the dendrite arbor has a
direct effect on the axon initial segment action potential onset (25). Consistent with
the premise that correct dendritic architecture is required for proper function,
patients with various neurological disorders exhibit atypical dendrite formation
(6,26–28).

Morphological changes in developing cortical neurons.
To demonstrate neuron morphological changes, plasmids encoding Green
fluorescent Protein (GFP) were introduced into NSCs of embryonic day (e) 14.5
mice by in utero electroporation (IUE) (Fig. 1.1A). IUE involves injecting plasmid
DNA into the lateral ventricle of a developing mouse embryo and applying an
electrical field using electrodes. By changing the directionality of the electrodes,
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selective targeting various regions of the cortex including the somatosensory
cortex (SSC) or the anterior cingulate cortex (ACC) could be achieved (Fig. 1.1B).
Neurons began to extend small basal cellular processes protruding from a small
elliptical soma by Postnatal day (P) 0, at which point the morphology of neurons in
the ACC and SSC were similar (Fig. 1.1E,F).
Cortical neuron dendrite complexity was assessed at P0 and P21 after
e14.5 IUE of CAG-GFP. The dendrite complexity at P21 was observed to be
significantly increased proximal to the soma (10–100 μm), having on average a
range of 2.5625 to 6.0 crossings compared to 0.0689 to 1.8275 crossings
(P<0.0001) (Fig. 1.1C-E). On average, SSC neurons had 1.3 basal dendrites at
P0, but this increased to 4.6 basal dendrites by P21 (P<0.0001) (Fig. 1.1C). These
results confirm that between P0 and P21 dendrite arborization occurs in cortical
neurons.
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Figure 1.1 Morphological changes in developing cortical neurons. A.
Schematic diagram of in utero electroporation. B. Electroporated
cerebral cortex outlined (upper) and schematic of electrode
directionality in relation to plasmid injection. C. Sholl analysis of P0
(black) and P21 (green) neurons in the somatosensory cortex (P0
N=29; P21 N=16). D. Quantification of the number of basal dendrites
in P0 and P21 neurons (P0 N=38; P21 N=34). E. Representative
image of GFP positive neurons at P0 and P21 in the ACC. F.
Representative image of GFP positive neurons at P0 and P21 in the
SSC. Scale bar=50 μm. ACC=Anterior Cingulate Cortex,
SSC=Somatosensory Cortex. ****=P<0.0001.
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mTOR activity in developing cortical neurons in vivo.
A major regulator of dendrite morphology in neurons is the serine threonine
kinase mammalian target of rapamycin complex 1 (mTORC1), which acts as an
anabolic growth regulator by promoting protein synthesis and translation in the
presence of amino acids and growth factors (20,29,30). mTORC1 is one of two
mTOR complexes, with mTORC2 being the second. mTORC1 controls cell growth
by phosphorylating p70S6 kinase (p70S6K) and 4EBP (31–33). p70S6K
subsequently phosphorylates the ribosomal S6 subunit (S6) (33–36). mTORC1 is
activated by the GTPase Ras homolog enriched in brain (Rheb) and is inhibited by
the GTPase activating protein complex encoded for by TSC1/2 (37,38). The mTOR
complexes are required for proper brain development (39,40). Knocking out mTOR
in NSCs reduces NSC proliferation and cortical thickness (39). Mutations in the
mTOR pathway cause epilepsy, intellectual delay, and neuropsychiatric comorbidities (41). Increased mTORC1 activity accelerates axon growth, increases
dendrite arborization, prevents autophagic pruning and leads to hyper-connectivity
(20,30,42,43). Thus, mTORC1 levels must be carefully titrated during neuron
development. The stringent regulation of mTOR activity and protein translation
during neurogenesis was recently highlighted in a previous study that examined
the role of mTOR activity in mouse NSC differentiation (44). Another study also
found changes in mTORC1 activity in human embryonic NSCs during
differentiation into neurons in vitro (45).
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To confirm the presence of mTOR, we performed immunohistochemical
analysis of coronal e14.5-16.5 brain sections for the phosphorylated form of S6
(Ser240/244), an established indirect downstream mTOR substrate. pS6 staining
at e14-16.5 was predominantly localized to DCX positive neuroblasts and enriched
in neuroblasts within the outer layers of the cortical plate (Fig. 1.2A,B). pS6
positive neuroblasts were also occasionally found in the ventricular zone (Fig.
1.2C). Levels of pS6 remained elevated at P0 in cortical neurons labeled with GFP
following e14.5 in utero electroporations (Fig. 1.2D-F). pS6 could be detected in
the ACC at P21, as well as in electroporated neurons in the SSC (Fig. 1.2G,H,I).
Taken together, the mTORC1 pathway is active in the developing brain in maturing
neurons.
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Figure 1.2 mTOR activity in developing cortical neurons in vivo. A. Coronal
section of e16 brain stained for pS6 (red), DCX (green), Topro-3 (blue). Scale
bar=150 μm. B. Cortical plate demonstrating pS6 (red) cells are DCX (green)
positive neuroblasts (Scale bar=50 μm). C. Image of ventricular zone
demonstrating that most pS6 (red) positive cells are DCX positive (green)
neuroblasts (Scale bar=50 μm). D. Coronal section of e14.5 electroporated
brain at P0 showing GFP positive cells (Scale bar=100 μm). E. P0 coronal
section shown in E showing pS6 (Scale bar=100 μm). F. Merge of GFP (green),
pS6 (red), and Topro-3 (blue) showing co-localization of mTOR activity in
neurons (Scale bar=100 μm). G. Coronal section of P21 brain showing pS6
staining in ACC (Scale bar=50 μm). H. 5× image of G from P21 brain showing
GFP (green) and pS6 (red) in ACC (Scale bar=150 μm). I. Coronal section of
P21 brain showing GFP (green), pS6 (red), and Topro-3 (blue) in SSC (Scale
bar=50 μm). ACC=Anterior Cingulate Cortex, SSC=Somatosensory Cortex.

10

Effect of perturbed mTOR activity during neuron development.
Effects on neuron morphology and dendrite complexity are phenocopied by
expression of constitutively active Rheb or Tsc1 knockout (30,42,46). Abnormal
dendrite patterning caused by mTOR hyper-activation is seen in focal cortical
dysplasia (FCD) and TSC models (30,42,47–49). Ectopic expression of
constitutively active or wild-type Rheb model FCDs. To the effect of perturbed
mTOR activity on neuron development, we performed IUE of wild-type Rheb.
Soma size was examined at P14 in control and Rheb expressing neurons. Rheb
expressing neurons had significantly larger and more complex dendrite arbors in
the ACC and SSC (Fig. 1.3A,B). Ectopic cells were found in lower layers of the
cortex (Fig. 1.3C,D).

Moreover, Rheb overexpression significantly increased

soma size (Fig. 1.3E). The misplaced cells in combination with an increased size
and hypertrophic dendritic arbors gave the appearance of a focal cortical
dysplasia-like lesion (Fig. 1.3F).
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Figure 1.3 Effect of perturbed mTOR activity during cortical neuron
development. A. Sholl analysis of control and Rheb ACC neurons at P14.
B. Sholl analysis of control and Rheb SSC neurons at P14. C.
Representative image of P14 control electroporated SSC neurons. D.
Representative image of P14 Rheb electroporated SSC neuron.
Quantification of SSC soma size. F. P14 Rheb electroporated neurons.
Scale bar=50 μm. ACC=Anterior Cingulate Cortex, SSC=Somatosensory
Cortex. *=P<0.05. ****=P<0.0001.
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Methods
In utero electroporation
In utero electroporation was performed by aseptic survival surgery on
embryonic day (e) 15.5-16 pregnant CD1 mice. Pregnant mice (e12) were acquired
from Charles Rivers laboratory and allowed to acclimate to cages for 3 days which
corresponds to an age of e15. Following acclimation, cages were placed into a
biological safety cabinet (BSC). Mice were assessed for signs of health. Weight,
approximate age, sex, and strain will be documented prior to surgery.
Documentation of grooming and physical activity and body temperature were
assessed. Mice were injected with 10 mg/kg buprenorphine 30 minutes prior to
anesthetization. Following intraperitoneal injection of analgesic, mice were
transported for surgery into a BSC. Mice were placed into an anesthesia induction
chamber and 3% isofluorane was applied. Following appropriate anesthetization,
mice were placed onto a pre-disinfected surgical table with a heat source and
attached to a nose cone with 2-3% isoflurane flow. Mice were shaved with #40
blade clippers and the skin prepared for aseptic surgery using triplicate, alternating
washes of chlorhexidine and sterile water. A midline ventral laparotomy was
performed. Uterine horns were slowly and carefully removed with ringed forceps
and a scoopula.
DNA solution (~1-1.5 μg/μl) diluted with PBS with 0.1% fast green was
made prior to surgery. DNA solution (0.5–1.0 μl) was injected into the lateral
ventricle using a pulled glass pipette. Glass pipettes were pulled with a P97 Sutter
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micropipette puller with the settings: Heat, 580; Pull, 20; Velocity, 40; Time, 100.
Pulled pipettes were irradiated in a sterile hood with UV light. DNA injection,
electrodes (model 520; BTX) were soaked in 0.9% saline solution and placed on
the heads of the embryos, and five, 30-volt square pulses of 50 ms duration with
950-ms intervals were applied using a pulse generator (ECM830; BTX). A
combination of plasmids encoding GFP, tomato, or Rheb under the chicken β-actin
promoter with CMV enhancer (CAG) was electroporated. After injection and
electroporation, abdominal muscles were closed with 5-6,1 cm absorbable sutures
(needle 5-0 C-1 (taper) 3/8 13 mm and skin closed with 3-5 9 mm autoclips. Mice
were subject to heightened monitoring of health and signs of deterioration for the
following two days. The date of birth of pups was recorded and mice sacrificed at
indicated time points.

Sholl analysis and cell size
Images of the anterior cingulate cortex and the somatosensory cortex were
uploaded to Fiji (ImageJ 1.51r/n). Dendrites were traced using the Simple Neurite
Tracer plug-in. The marking tool was used to trace the projections from the soma
to the projection terminus. Sholl analysis was performed at 10 μm intervals to a
maximum radius of 400 μm to quantify dendritic arborization using the Fiji Sholl
plug-in. The longest dendrite was selected as the primary apical dendrite and
length calculated by simple neurite tracer. Basal dendrites were quantified by
Simple Neurite Tracer as dendrites localized to the bottom two thirds of the soma.
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To measure cell size, Z-stack images of GFP+ cells coronal sections were
acquired with a ×20 dry objective (Numerical Aperture, 0.75) using high-low
settings to minimize saturation. In Image J, the freehand tracing tool was used to
outline cell somas. Cell size was represented relative to the indicated controls.

Slice preparation and immunohistochemistry
Mice were deeply anesthetized where appropriate with pentobarbital (50
mg/kg) or on ice (P0 pups) and decapitated. The brain was removed in PBS and
placed in 4% paraformaldehyde in PBS and incubated for 4 hours at room
temperature (e12-P0) or overnight at 4°C, then washed in PBS. The region of
electroporation was imaged using a Nikon AZ100. The next day, 300-μm-thick
slices were prepared using a vibratome (Leica VTS 1000). Immunostaining was
performed in free-floating 300-μm-thick slices. Free-floating sections were blocked
in PBS containing 0.1% Triton X-100, 0.1% Tween-20, and 2% BSA and incubated
in primary antibodies (see below) overnight at 4°C. After three washes in PBS
containing 0.1% Tween-20, slices were incubated with the appropriate secondary
antibody (Alexa Fluor series at 1:500 [Invitrogen]) for 1 hour at room temperature
or overnight at 4 degrees C. Primary antibodies were goat anti-DCX (1:500; Santa
Cruz Biotechnology Inc.) and rabbit anti-pS6 (1:1,000; Cell Signaling; Ser240/244,
61H9, #4838). Each staining was replicated in at least 3-5 different mice. Z-section
images were acquired on a spectral confocal microscope (Leica SPE) with a ×20
dry objective (N.A. 0.75) or ×63 oil immersion objective (N.A. 1.5). Low-
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magnification images were acquired with a ×5 dry objective. Images were analyzed
and reconstructed using ImageJ 1.51r software or Photoshop CS6.

Hypothesis
Taken together, mTORC1 is required for neuron development. In addition,
mTORC1 activity is dynamic and carefully titrated during neurodevelopment
(44,45). While the role of mTORC1 is to support anabolic growth during this
developmental window, mTORC1 activity fluctuation also means that upstream
mTORC1 regulators and downstream substrates likely require precise regulation
for proper development to occur. Thus, alterations in components of the mTOR
pathway could prove detrimental to neuron development.
One downstream candidate of mTORC1 is Unc-51 like autophagy
activating kinase 1 (Ulk1), a pro-autophagic kinase that is inhibited by mTORC1
via Ulk1 phosphorylation at Serine 757 (Ser757). Ulk1 may be a valuable target
for therapeutic intervention in neurodevelopmental disorders stemming from
upregulated mTOR activity. TSC studies have shown altered autophagy activity
that may be the result of mTORC1 dependent inhibition of Ulk1 (43).
An upstream candidate is the solute carrier family 7 member 5 (Slc7a5), a
neutral amino acid transporter that regulates mTORC1 activity by shuttling certain
amino acids including leucine (50–52). Slc7a5 inactivation is a cause of autism
spectrum disorder and leads to neurodevelopmental defects in mouse models
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embryonically (53,54). An upregulation of SLC7A5 was detected in TSC patient
balloon cells (55). Additionally, Slc7a5 regulates Kv1.2 channels in vitro (56).
Herein, we propose to define the role of Slc7a5 and Ulk1 in mouse neuron
development through in vivo techniques. We will then apply this insight into
developing a NSC conditional transgenic Tsc2 knockout mouse colony that can be
used as a model to study aberrant neuron development. Based on the clear role
of the mTOR pathway in neuron development, I propose that two components of
the mTOR pathway, Ulk1 and Slc7a5, are involved with regulating neuron
development. Additionally, using a conditional NSC specific Tsc2 knockout mouse
model would provide valuable insight into neuron development and defects
resulting from upregulated mTOR activity.
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CHAPTER II
Role of Ulk1 kinase in cortical neuron development
Abstract
The cerebral cortex development process involves vast amounts of cell
growth and increases in dendrite complexity by cortical neurons. The anabolic
growth regulator mammalian target of rapamycin complex one (mTORC1) has a
well-established role in these morphological changes. Due to the importance of
mTORC1 in development, it is likely that other components of the mTORC1
pathway play a role in development. One mTORC1 substrate, Ulk1, is a proautophagic kinase that is also involved in Golgi-ER transport and is inhibited by
mTORC1 via phosphorylation at Ulk1 Serine 757 (Ser757). Loss-of-function
studies have demonstrated that Ulk1 is required for proper neuron development
and maturation in mice. However, gain-of-function approaches have not
addressed whether ectopic Ulk1 expression is sufficient to disrupt neuron
development, and what role mTORC1 has in Ulk1 regulation during this period of
growth. Here mTORC1 activity, Ulk1, and Ulk1 inhibitory phosphorylation at
Ser757 were confirmed to be present in developing pyramidal neurons undergoing
dendrite outgrowth in the cortex. A CAG-Ulk1 plasmid was constructed and
introduced into NSCs of the ventricular zone by IUE. Migration was unaltered, but
neuron dendrite arborization was decreased by P14 compared to controls.
Moreover, a notable divergence in Ulk1 overexpressed neurons manifested, with
a subset developing with relatively normal morphology. Ulk1 overexpression was
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found to induce elevated inhibitory Ulk1 Ser757 phosphorylation in a subset of
developing neurons and this expression was associated with improved dendrite
arborization compared to neurons with low pUlk1 Ser757 expression. We propose
that mTORC1 regulates Ulk1 activity in developing neurons, with ectopic Ulk1
leading to defective dendrite outgrowth unless inhibited.
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Introduction
As described in chapter I, a major regulator of dendrite morphology in
neurons is the serine threonine kinase mTORC1, which acts as an anabolic growth
regulator by promoting protein synthesis and translation in the presence of amino
acids and growth factors (20,29,30). For this reason, we speculate that the
downstream substrate of mTORC1, Ulk1, requires equally stringent regulation for
proper development to occur (57–59).
Unc.51 was identified in a mutational screen in C. elegans (60). Unc.51
mutations caused paralysis and uncoordinated motor activity due to abnormal
motor neuron development (60,61). Notably, alterations in Unc.51 led to defective
axon growth, premature termination, and mislocalization (62,63). The homolog of
Unc.51, Ulk1, is likewise expressed within mammalian neurons where the
introduction of a dominant negative form inhibits neurite outgrowth (64). Both Ulk1
and the homolog Ulk2 were found to localize to sensory neuron axon growth cones
(65). RNAi of Ulk1 in mammalian sensory neurons caused spurious axon
arborization and prevented axon growth (65). As further evidence that Ulk1
regulates neuron morphology, Ulk1/2 double knockout forebrains have defects in
all major cortical axonal tracts including the corpus callosum and anterior
commissure (66).
The fact that Ulk1/2 inhibition causes developmental defects is surprising
because Ulk1 is an established pro-autophagic protein. Typically, metabolic stress
activates Ulk1 which subsequently phosphorylates Beclin1 and VPS34 (67). An
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example of a metabolic stress is that glucose starvation activates AMP Kinasedependent Ulk1 phosphorylation and autophagy (68). AMP Kinase (AMPK)
phosphorylates Ulk1 at serine 555, 317, and 777 (68–70). However, AMPK is
inactive during neuronal maturation and is dispensable for cortical development
(71). Interestingly, AMPK activation during development prevents axon and
dendrite outgrowth (71,72). This is likely caused by AMPK activation of TSC2,
which in turn inhibits mTORC1. In addition, AICAR treated neurons activates
AMPK and AKT (72). Although AMPK is inactive during neuronal maturation, loss
of Ulk1/2 causes neuronal degeneration (73). It is unclear to what extent this is
due to abnormal autophagy. For example, autophagy gene knockouts do not
phenocopy Ulk1/2 axon defects (66). Moreover, Ulk1/2 double-knockouts do not
have autophagy defects (66,73). Therefore, alternative roles for Ulk1/2 in the brain
are likely. For example, Ulk1/2 phosphorylation of SEC16 regulates ER to Golgi
trafficking in neurons (73).
To investigate the role of Ulk1 in neuron development, herein experiments
are presented that examine the state of Ulk1 and mTORC1 in developing mouse
cortical neurons in vivo and the effect of ectopic Ulk1 expression.

Methods
Animals
Experiments were approved by the Clemson University Institutional Animal
Care and Use Committee. Experiments were performed according to guidelines
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set forth by the Clemson University Institutional Animal Care and Use Committee
and NIH Guide for the Care and Use of Laboratory Animals. For primary cell culture
experiments and neonatal electroporation, pregnant CD-1 mice were obtained
from Charles River Laboratories. Mice were housed under pathogen-free
conditions with a 12-hr light/dark cycle.

In utero electroporation
Performed as described in chapter I using a combination of plasmids
encoding GFP under the chicken β-actin promoter with CMV enhancer (CAG), or
CAG-Ulk1 plasmids.

Neuro-2A cell culture and transfection
Neuro-2a mouse neuroblastoma cells (American Type Culture Collection
CCL-131) were grown in tissue culture-treated polystyrene multi-well plates or
flasks (Falcon; BD Biosciences Discovery Labware) in a 5% CO2 37°C incubator.
Neuro-2a cells were routinely propagated and DNA transfections were performed
with PolyJet (SignaGen Laboratories). Initially 4 x 105 cells were seeded into 6 well
plates or 2 x 105 cells into 12 well plates 24 hours prior to transfection. 72 μl Polyjet
was mixed with 1.2 ml DMEM and then 600 μl of this solution was added to test
tubes containing 6 μg of DNA in 600 μl DMEM. After ten minutes, 200 μl of
polyjet/DNA solution was added to each well for a final concentration of 1 μg of
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tdTomato (Addgene # 83029) or CAG-Ulk1 per well. For starvation experiments,
cells were put in DMEM lacking Fetal Bovine Serum.

Sholl, colocalization, and cell size analysis
Images were uploaded to Fiji (ImageJ 1.52e) and using the Simple Neurite
Tracer plug-in, dendrites were traced from the soma to the projection terminus.
Sholl analysis was performed at 10 μm intervals to quantify dendritic arborization
using the Sholl plug-in.
The freehand tracing tool in Fiji allowed for quantification of cell size by
measuring cell soma area using 20x dry objective Z-stack images (Numerical
Aperture, 0.75) of GFP+ cells in coronally sliced brains.
The cell counter tool using combined channels along with the channels tool
allowed for quantification of the number of cells that were both GFP and pS6
positive and thus colocalized.

Slice preparation and immunohistochemistry
Performed as described in Chapter I using rabbit anti-pUlk1 757 (1:500; Cell
Signaling Technology; D7O6U, #14202), rabbit anti-Ulk1 (1:500; Cell Signaling
Technology; D8H5, #8054), rabbit anti-pS6 (1:500; Cell Signaling Technology;
Ser240/244, 61H9, #4838), or mouse anti-NeuN (1:500; Millipore Sigma;
MAB377).

23

Primary neuron culture
Pregnant e16.5 mice were anesthetized, uterine horn removed and placed
on ice. Embryos were removed and brains were dissected into chilled DMEM
(Invitrogen). Cortices were extracted and placed into 12 mL of chilled DMEM in a
15 mL conical tube. Following dissection of embryos, cortical tissue was
transferred into a TI75 flask containing DMEM with 50 micromolar dAPV, 10 U/mL
papain, and 0.25 mg/mL L-cysteine. Following a 15-minute incubation at 37°C,
dissociated tissue was next transferred to a 15 mL conical tube and gently
triturated with fire polished glass pipettes. Following a 300 x g spin for 5 minutes,
the supernatant was decanted and pellet resuspended in warm Neurobasal Plus
(Invitrogen) complete media (2% B27 plus, 1X Glutamax, 50 ng/mL BDNF, 50
ng/mL IGF1, and 50 μM dAPV). Cells were counted using a hemocytometer and
plated at 1 x 105 on poly-D-lysine coated wells containing coverslips. The next day,
half the media was replaced with fresh media, and this was repeated every 3 days.
Experiments were performed 7 days later.

Pharmacological Treatments
Neurons were treated with the indicated amounts of Rapamycin (#9904s, Cell
Signaling Technology) or Torin1 (#14379, Cell Signaling Technology). Torin1 was
re-constituted in DMSO (MP Biomedicals) for a 1mM stock. Rapamycin was reconstituted in DMSO for a 100 mM stock. Eqi-molar DMSO was used for all
conditions. Cultured neurons were treated for 2 hours. Western blot samples were
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collected in 2% SDS in RIPA buffer containing protease and phosphatase inhibitor
cocktail. Lysates were briefly sonicated on ice and centrifuged at 13,200 rpm for
10 minutes in a tabletop Eppendorf 5414 centrifuge. Proteins were resolved by
standard electrophoresis conditions on 12% polyacrylamide precast mini-Protean
TGX gels and transferred to polyvinylidene difluoride (PVDF) membranes.
Membranes were rinsed in TBST (Tris-buffered saline, 0.1% Tween 20) for 5
minutes at room temperature and subsequently blocked in 5% w/v nonfat milk in
TBST for 1 hour at room temperature. Samples were incubated overnight at 4°C
with the following antibodies: rabbit anti-pS6 (1:1,000; Cell Signaling Technology;
Ser240/244, 61H9, #4838), rabbit anti-total S6 ribosomal protein (1:1,000; Cell
Signaling Technology; 5G10, #2217), rabbit anti-pUlk1 757 (1:1,000; Cell
Signaling Technology; D7O6U, #14202), rabbit anti-pBeclin1 15 (1:1000; Cell
Signaling Technology; D4B7R, #84966), rabbit anti-total Beclin1 (1:1000; Cell
Signaling Technology; D4B7R, #84966), and rabbit anti-total Ulk1 (1:1000; Cell
Signaling Technology; D8H5, #8054). Following an additional five rinses each of
10 minutes in TBST, samples were incubated for 1 hour at room temperature with
donkey or goat anti-rabbit antibodies in blocking buffer and then subjected to four
15-minute washes in TBST and visualized using enhanced chemiluminescence
with film. All phospho-antibody/total antibody ratios were quantified using the same
PVDF membrane. PVDF membranes were briefly stripped for 5-15 minutes at
room temperature using Restore Western Blot Stripping Buffer (#21059, Thermo
Fisher Scientific) before re-probing for total levels of that protein. Films were
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scanned as tiff files at 600 dpi in color format with an HP Officejet Pro 8600 scanner
and subjected to densitometric analysis.

Phosphatase experiments
Neuro-2a cells were transfected and lysate collected for western blot as
described above. Following transfer, the PVDF membrane was cut in half so both
contained six lanes each (3 control and 3 Ulk1). One of these halves was subjected
to Lambda protein phosphatase (Sigma-Aldrich; P9614) treatment for four hours,
followed by an alkaline phosphatase (Sigma-Aldrich; P0114) treatment for 30 more
minutes. Blots were then washed, blocked, and probed as described above.

Statistics
Data were analyzed with Prism (Version 8; GraphPad). Statistical
significance was determined by Student’s T-test (Colocalization analysis, # of
crossings, cell size, western blots), One way ANOVA (Western blots with >3
conditions) with multiple comparisons test, or two-way ANOVA with Tukey’s
correction (dendrite arborization) followed by multiple comparison’s test.
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Results
Late stage developing cortical neurons undergo morphological changes.
To begin, we performed IUE into the LV at age e15.5 to allow visualization
of neurons with GFP (Fig. 2.1A,B). To ascertain the state of the labeled neurons,
morphological changes between P14 and P30 were quantified. While soma size
did not change, dendrite complexity significantly increased from P14 to P30
(P<0.001) (Fig. 2.1C,D).
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Figure 2.1 Late stage developing cortical neurons undergo
morphological changes. A. Morphology of P14 GFP electroporated
neurons in the SSC following IUE. B. Morphology of P30 electroporated
neurons in the SSC following IUE. C. Soma Size analysis of P14 and
P30 neurons in the SSC (P14 N=3, n=69; P30 N=5, n=113). D. Sholl
analysis of P14 and P30 neurons in the SSC (P14 N=3, n=39; P30 N=3,
n=28). SSC=Somatosensory cortex. IUE=In utero electroporation.
Scalebar=50 µm. ***=P<0.001.
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mTORC1 activity is present in the developing cortex.
Immunohistochemistry (IHC) at P14 and P30 confirmed pS6 Ser240/244 is
present in cortical neurons, and thus mTORC1 is active (Fig. 2.2A-D).
Interestingly, the number of GFP positive neurons that colocalized with pS6
decreased from ~40% to ~10% between P14 and P30, indicating that as neurons
complete development mTOR activity is reduced (P<0.001) (Fig. 2.2E). Finally, to
confirm the pS6 staining labeled mature neurons, slices were co-stained with
NeuN and pS6 (Fig. 2.2F,G). Taken together, between P14 and P30 mTORC1
activity is correlated with continued dendrite outgrowth but not increasing soma
size in cortical neurons.
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Figure 2.2 mTORC1 activity is present in the developing cortex. A,B.
PS6 immunohistochemistry on P14 SSC after GFP IUE. C,D. PS6
immunohistochemistry on P30 SSC after GFP IUE. E. GFP and pS6
colocalization analysis P14 versus P30 (P14 N=8; P30 N=6). F,G. NeuN
and pS6 immunohistochemistry at P21. SSC=Somatosensory Cortex.
IUE=In utero electroporation. Scalebar=50 µm. ***=P<0.001.
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Ulk1 is present in cortical neurons and phosphorylated by mTORC1 at Ser757.
IHC confirmed the presence of both Ulk1 and Ulk1 inhibitory
phosphorylation at Ser757 in developing cortical neurons in vivo (Fig. 2.3A,B).
Additionally, Ulk1 and pUlk1 Ser757 were detected in cortical lysate from P14 to
P30 (Fig. 2.3C). Since pUlk1 Ser757 and pS6 were found in cortical neurons
during development, in vitro pharmacological experiments using the mTOR
inhibitors Torin1 and rapamycin were performed to confirm the relationship
between mTOR and Ulk1 (Fig. 2.3D). Torin1 significantly reduced pUlk1 Ser757
levels in primary cultured neurons (P<0.05), with rapamycin reducing levels to a
lesser extent.
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Figure 2.3 Ulk1 is present in cortical neurons and phosphorylated by
mTORC1 at Ser757. A. Ulk1 IHC from P14 control cortex. B. NeuN and
pUlk1 757 IHC from P7 cortex. C. Representative western blots of pUlk1
Ser757, Ulk1, and Akt in dissected cortical tissue lysate at indicated
timepoints (N=6,6,6). D. Western blots of pUlk1 Ser757, Ulk1, and Akt
following equimolar DMSO,100 nM rapamycin, or 100 nM Torin1 treatment
in primary neurons (N=2,2,2). E. F. Scalebar=50 µm. *=P<0.05. IHC=
Immunohistochemistry.
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Ectopic Ulk1 is phosphorylated at Ser757 and Ser555 in vitro.
Ulk1 was transfected into Neuro-2a cells to test the hypothesis that
increased Ulk1 leads to increased Ulk1 activity. Ulk1 expression under a CAG
promoter was significantly enhanced (P<0.0001), but phosphorylation of the Ulk1
substrate Beclin1 was not increased (Fig. 2.4A,B). Beclin1 phosphorylation,
however, was increased by starvation (P<0.05) (Fig. 2.4A,B). Since Ulk1 activity
was not increased by Ulk1 expression, we measured Ulk1 Ser555 stimulatory
phosphorylation. pUlk1 Ser555 was markedly increased in Ulk1 transfected Neuro2a cells (P<0.001) (Fig. 2.4C,D). This eliminated the possibility that a lack of
Ser555 phosphorylation prevented full Ulk1 activation. Another potential
mechanism that prevents Ulk1 activity is mTOR dependent inhibitory Ulk1 Ser757
phosphorylation. We therefore quantified Ulk1 Ser757 phosphorylation and found
a marked increase in Ulk1 transfected cells (P<0.001) (Fig. 2.4C,D).

33

Figure 2.4 Ectopic Ulk1 is phosphorylated at Ser757 and Ser555 in vitro. A.
Quantification of Ulk1/GAPDH and pBeclin1/Beclin1 in GFP control or Ulk1
transfected Neuro-2a cells (N=3,3,3,3). Cells were cultured in complete
media or starved. B. Representative western blots from A. C. Quantification
of pUlk1 Ser757/GAPDH and pUlk1 Ser555/GAPDH in GFP control or Ulk1
transfected Neuro-2a cells (N=3,3,3,3). Cells were cultured in complete
media or starved. D. Representative western blots for C. *=P<0.05,
***=P<0.001, ****=P<0.0001.
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Specificity of phospho-Ulk1 antibodies
Given the extraordinarily robust stimulation of Ulk1 phosphorylation,
phospho-antibody cross-reactivity to total Ulk1 was a concern. However,
phosphatase treatment eliminated pUlk1 Ser757 (P<0.0001) and pUlk1 Ser555
expression (P<0.0001) (Fig. 2.5A-C,I). To begin to explore the role of Ulk1 in
neuron development, e15 cortical neurons were electroporated with Ulk1 and GFP,
removed 24 hours later, and cultured for 7 days in vitro (DIV) (Fig. 2.5D-H). Ulk1
electroporated neurons had an approximate 3-fold increase in pUlk1 Ser757 and
no detectable change in pUlk1 Ser555 in comparison to control neurons (Fig. 2.5EH). These results demonstrate that ectopic Ulk1 expression increases pUlk1
Ser757 in vitro.
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Figure 2.5 Specificity of phospho-Ulk1 antibodies. A,B. Western blots of pUlk1
Ser757, pUlk1 Ser555, and total Ulk1 from GFP control or Ulk1 transfected
Neuro-2a cells with or without phosphatase treatment. C. Quantification of
pUlk1 Ser757 in A (N=3,3,3,3). D. Primary neuron cultures at 7 DIV. E-H. Ulk1
and GFP electroporated neurons (green) stained for pUlk1 Ser757 (E, F) or
pUlk1 Ser555 (G, H). I. Quantification of pUlk1 Ser555 in B (N=3,3,3,3).
DIV=days in vitro. ****=P<0.0001.

Ectopic Ulk1 expression leads to defective neuron development.
Next, IUE with Ulk1 and GFP were performed in mice, with brains collected
at P14 and labeled neurons examined for any defects. Sholl analysis revealed that
a large percentage of Ulk1 overexpressed neurons had decreased dendrite
complexity (Fig. 2.6A-C,F). Interestingly, when the total number of crossings were
visualized in a percent frequency diagram it was observed that a subset of Ulk1
overexpressed neurons had dendrite complexity within the range of control
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neurons (Fig.2.6C). We next sought to determine why there was a divergence in
dendrite complexity. Neurons with elevated levels of pUlk1 Ser757 correlated with
increased complexity compared to low pUlk1 Ser757 (P<0.0001) (Fig. 2.6D,E).
High pUlk1 Ser757 expression was defined as cells that had increased mean
intensity by region of interest analysis compared to surrounding nonelectroporated
cells in the same plane.
Taken together, these results provide evidence that pUlk1 Ser757
phosphorylation is required for neuron development, with ectopic Ulk1 expression
causing defects unless inhibited. In this model, mTORC1 keeps Ulk1 levels in
check during development.
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Figure 2.6 Ectopic Ulk1 expression leads to defective neuron development.
A,B. Morphology of P14 GFP control or Ulk1 electroporated neurons in the SSC
following IUE. C. Percent frequency histogram for the number of crossings of
each P14 Control GFP and Ulk1 neurons (Control N=3, n=39; Ulk1 N=4, n=37).
D. IHC of pUlk1 Ser757 in Ulk1 electroporated neurons following IUE. E.
Number of crossings analysis on P14 Ulk1 neurons with high versus low pUlk1
757 expression (High N=3, n=19; Low N=3, n=21). F. P14 number of crossings
analysis for all control versus Ulk1 electroporated neurons (Control N=3, n=39;
Ulk1; N=4, n=37). OX=Overexpressor. Scalebar=50 µm. ****=P<0.0001.

Discussion
The goal of this study was to the ascertain the role of Ulk1 regulation in
cortical neuron development using a gain-of-function approach, with a focus on
potential dendritic morphological regulation. To begin, the Ulk1 regulator mTORC1
was confirmed to be active in cortical neurons during development. Additionally,
the percent colocalization of GFP with pS6 decreased as the neurons mature.
Since plasmids dilute over time, GFP labeled neurons share similar birthdates.
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This means that levels of mTORC1 activity decrease as neurons complete the
maturation process. At P14, ~40% of GFP positive neurons were pS6 positive
compared to under 10% percent at P30. In the same time frame, cortical neurons
underwent basal dendrite outgrowth. The levels of growth were consistent based
on timepoints analyzed in our prior studies (20). Based on the findings of both
papers, it demonstrates that dendrites are growing more rapidly from P0 to P21,
with a change in peak complexity within 100 microns over 4 crossings, compared
to ~2.5 crossings from P14 to P30.
To confirm if the established relationship between mTOR and Ulk1 is
conserved in the brain, in vitro pharmacological experiments using the mTOR
inhibitors Torin1 and rapamycin were performed on primary mouse neurons.
Torin1, and to a lesser extent rapamycin, reduced pUlk1 Ser757 levels. This
indicated that just like reported in other systems, mTOR is indeed regulating Ulk1
in neural cells. Additionally, Ulk1 and pUlk1 Ser757 is readily detected both by
western blot of cortical lysates, as well as by IHC of the cerebral cortex in vivo.
Interestingly, since pUlk1 Ser757 was also detected, it was tempting to speculate
that this inhibition is required for neuron development, with mTORC1 keeping Ulk1
activity in check.
In utero electroporations were performed using a CAG Ulk1 plasmid coelectroporated with GFP at e15.5. A co-requisite for in utero electroporation is the
use of a CAG promoter to drive target protein expression because many promoters
are inactive in neurons by P14 (74). CAG promoter driven Ulk1 resulted in
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defective dendrite outgrowth. This is not surprising due to the necessity of Ulk1
evident from previous knockout studies (66). Interestingly, during examination we
observed Ulk1 overexpressed neurons that exhibited relatively normal dendrite
complexity compared to controls. Due to the presence of endogenous pUlk1
Ser757 phosphorylation, we wondered to what extent mTOR activity could be
inhibiting the overexpressed Ulk1. To test this, we performed IHC for pUlk1 Ser757
and found that a subset of Ulk1 overexpressed neurons exhibited heightened
pUlk1 Ser757 levels. Moreover, the neurons with increased pUlk1 Ser757
expression on average had a morphology comparable to controls. This would
indicate that not only does ectopic Ulk1 have detrimental effects on neuron
development, but also that mTORC1 inhibition of Ulk1 by Ser757 phosphorylation
is required. Taken together, these findings provide evidence that Ulk1 inhibition is
required for proper neuron development, and ectopic Ulk1 results in defective
morphology if not inhibited. In this model, neuron Ulk1 activity is thus kept in check,
likely by mTORC1 activity.
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CHAPTER III
Role of amino acid transporter Slc7a5 in granule cell development

A version of this data is published in Human Molecular Genetics:
Sokolov, A. M., Holmberg, J. C. and Feliciano, D. M. (2020) The amino acid
transporter Slc7a5 regulates the mTOR pathway and is required for granule cell
development. Hum. Mol. Genet.
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Abstract
Pathogenic mutations in the SLC7A5 gene, which encodes an amino acid
transporter, causes microcephaly and seizures. However, the mechanisms
responsible for these phenotypes are unclear. Models have demonstrated that
mouse Slc7a5 deletion is embryonic lethal and that these embryos lack a fully
formed telencephalon. This phenotype is similar to mTOR deletion or inhibition.
Notably, in many cells Slc7a5 import of amino acids is required to maintain mTOR
activity. Slc7a5 is present within neurogenic regions during embryogenesis, is
found in cultured neurons, and can modulate neuronal electrophysiological
properties. However, Slc7a5 is also highly expressed within endothelial cells of the
blood-brain barrier where removal in conditional mice leads to severe behavioral
defects and non-cell autonomous changes in neurons. Therefore, the extent that
neural Slc7a5 is required for development is unclear.
Here, subventricular zone neural stem cells that generate olfactory bulb
granule cells were electroporated with SLC7A5 or Slc7a5 short hairpin RNA
encoding plasmids. Although early phases of neural development were unaltered,
Slc7a5 knockdown effected late phases of granule cell dendrite maturation and
survival. Slc7a5 knockdown also decreased mTOR pathway activity. Ras homolog
enriched in brain, an mTOR activator, rescued the effect of Slc7a5 knockdown on
mTOR pathway activity and dendrite arbors. The data presented here demonstrate
that Slc7a5 is required for granule cell mTOR pathway activity, maturation, and
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survival, which may help explain why Slc7a5 mutations prevent normal brain
development and function.
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Introduction
Inactivating mutations in the SLC7A5 gene lead to a neurodevelopmental
disorder

characterized

by

microcephaly,

seizures,

and

neuropsychiatric

manifestations (53). SLC7A5 single nucleotide polymorphisms, copy number
variants, and altered expression are also associated with a wide range of
neuropathologies (55,75–79). Slc7a5 deletion is embryonic lethal and leads to
robust neural defects in mice (52,54). Slc7a5 is expressed within embryonic
cultures of cortical neurons, the developing neural tube and forebrain, and in
postnatal neurogenic regions (54,80,81). Slc7a5 also regulates Kv1.2 dendritic
voltage gated potassium channels in developing hippocampal neurons (56). Thus,
at first appearance, Slc7a5 seems to play an important role in nervous system
development. However, expression is notably absent from mature neurons in the
adult nervous system where it appears confined to endothelial cells of the blood
brain barrier (BBB) (53,82). Slc7a5 deletion from the developing BBB causes
behavioral defects and changes in neuronal excitatory/inhibitory balance in mice
(53). Notably, mice with Slc7a5 deletion from the BBB had no reported brain
architectural defects whereas patients with Slc7a5 mutations and Slc7a5 knockout
mouse brains are severely altered (53,54). Therefore, whether Slc7a5 has a cell
autonomous role in neural cells requires further clarification.
Slc7a5 is an evolutionarily conserved transporter that facilitates cellular
uptake of neutral amino acids (83–85). Slc7a5 is associated with Slc3a2 in a
heteromeric complex and together function as an amino acid antiporter (50).
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Notably, Slc7a5 transports leucine into cells (50,83). Leucine is an anabolic amino
acid that stimulates the protein kinase mTOR, resulting in protein translation and
cell growth (86–94). Leucine binds to and prevents an interaction between Sestrins
and a protein complex called GATOR2 (89). This allows GATOR2 to inhibit a
GTPase activating protein, GATOR1 (89,91). GATOR1 inhibits lysosomal RAG
heterodimeric GTPases that are responsible for mTOR docking at the surface of
the lysosome (90). mTOR docking at the lysosome is required for mTOR activity
because the GTPase Rheb is also localized to the lysosome with TSC1/2, which
are Rheb GTPase activating proteins (37,38). Amino acids cause TSC1/2
lysosomal dissociation, mTOR docking at the lysosome with RAGs, and mTOR
activation by Rheb. Therefore, amino acids regulate the mTOR pathway (Figure
3.1A,B).
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Figure 3.1 Leucine induces mTORC1 activity through the Sestrin2Rag GTPases signaling cascade. A. The Sestrin2-Rag GTPase
signaling cascade without leucine. B. The Sestrin2-Rag GTPase
signaling cascade with leucine, resulting in mTORC1 recruitment to
the lysosomal surface to be activated.
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Here I performed electroporations neonatally as opposed to in utero, where
the plasmid is injected into the lateral ventricle at P0. Subventricular zone (SVZ)
NSCs located along the lateral ventricles comprise the largest postnatal
neurogenic compartment in the brain (95). SVZ NSCs generate neuroblasts that
migrate through the rostral migratory stream (RMS) into the olfactory bulb (OB)
where approximately 94% mature into inhibitory granule cells (GCs) (95–99). GCs
typically form dendrodendritic reciprocal synapses via their apical dendrite with
mitral and tufted cells of the olfactory bulb. The role of Slc7a5 in SVZ neurogenesis
and GC maturation was examined. RNA interference (RNAi) resulting in Slc7a5
knockdown in vivo dramatically altered late phases of GC dendrite maturation and
GC survival. Furthermore, Slc7a5 knockdown reduced mTOR pathway activity.
Importantly, mTORC1 activation rescued Slc7a5 knockdown effects on GC
maturation. The results of this study provide evidence that Slc7a5 regulates GC
mTOR pathway activity and is required for late phases of dendrite maturation and
survival.

Methods
Plasmids
CAG-Rheb (a kind gift from Dr. Seonhee Kim) and CAG-tdTomato
(Addgene #83029, a kind give from Dr. Angelique Bordey) have been described
elsewhere (65,66). CAG-SLC7A5 was synthesized by a commercial vendor
(SignaGen Laboratories). shSlc7a5 (Sigma Aldrich, TRCN0000443348 and
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supplemental TRCN0000426198), control (Sigma Aldrich empty vector), CAGGFP (Addgene #11150) and CMV-myc-Slc7a5 (Slc7a5 NM_011404 Mouse
Tagged ORF Clone, Origene) plasmids are available through the indicated
commercial vendors.

Neuro-2a cell culture and transfection
Neuro-2a mouse neuroblastoma cells (American Type Culture Collection
CCL-131) were maintained in Dulbecco’s modified Eagle’s medium (DMEM), 10%
fetal bovine serum, and penicillin/streptomycin in tissue culture-treated polystyrene
flasks (Falcon; BD Biosciences Discovery Labware) in a 37°C incubator with 5%
CO2. Neuro-2a cells were passaged at a density of 4 x 105 cells into 6 well plates
24 hours prior to transfection. PolyJet (SignaGen Laboratories) was mixed at a 3:1
ratio with plasmid DNA in DMEM and approximately 1 µg of plasmid was added to
each well.

Neonatal electroporation
Timed pregnant CD-1 mice were delivered from Charles River Laboratories,
acclimated to the animal facility, and the date of birth was recorded. Neonatal mice
(P0-P1) were injected with equal amounts, concentrations, and volumes of DNA
plasmids (~1.3-2.0 µg/µL) diluted in PBS with 0.1% fast green. DNA was injected
into the lateral ventricles illuminated with a fiber optic light source and delivered
using a UV sterilized borosilicate glass micropipette generated from capillary tubes
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as previously described (67). Borosilicate capillary tubes were pulled with a P97
Sutter micropipette puller with the settings. Tweezer electrodes (model 520; BTX)
were rinsed in 0.9% saline solution and placed on the heads of the pups, and five,
100-volt square pulses of 50 ms duration with 950-ms intervals were applied using
a pulse generator (ECM830; BTX).

Image analysis
20× images were uploaded and analyzed using Fiji (ImageJ 1.5g). Simple
Neurite Tracer plug-in was used to trace dendrite processes of 23-58 RFP positive
cells from 3-6 mice per condition. Sholl analysis was performed at 10 µm intervals
to quantify both apical and basal dendritic arborization using the Sholl plug-in. Total
number of dendritic crossings were calculated by taking the sum of crossings at 1
μm intervals for each traced neuron and averaging the total number of crossings
per neuron in each condition. The number of labeled OB GCs from 3-8 mice was
quantified using Fiji cell counter plugin. 20× images of RFP positive OB GCs
stained by immunohistochemistry were uploaded to Fiji (ImageJ 1.5g). The
freehand selection tool was used to trace a region of interest on electroporated
cells and record a mean gray value to quantify the staining intensity of pS6 in
indicated conditions. Pairwise comparison of staining in non-electroporated cells
in the same Z section was performed. Staining was performed on 3-5 mice per
condition and 33-60 cells per condition.
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Slice preparation and immunohistochemistry
Performed as described in Chapter I. Primary antibodies used were pS6
(rabbit anti-pS6; 1:1000; Cell Signaling Technology; Ser 240/244, 61H9, #4838),
or SLC7A5 (rabbit anti-SLC7A5; 1:1000; Cell Signaling Technology; #5347)
overnight at 4°C. After three washes in PBS containing 0.1% Tween-20, slices
were incubated with the appropriate secondary antibody (Alexa Fluor series at
1:500 [Invitrogen]) overnight at 4°C. TO-PRO-3 (Invitrogen) was used to counterstain sections. Each staining was replicated on 4-6 mice per condition.

Western blotting
Performed as described in Chapter II with the following antibodies: rabbit
anti-SLC7A5 (1:1,000; Cell Signaling Technology; #5347), rabbit anti-myc-tag
(1:1,000; Cell Signaling Technology; 71D10, #2278), and rabbit anti-Akt (pan)
(1:1,000; Cell Signaling Technology; 11E7, #4685). Blots were visualized using
Bio-Rad Chemidoc MP imaging system. PVDF membranes were stripped for 5-15
min at room temperature using Restore Western Blot Stripping Buffer (#21059,
Thermo Fisher Scientific) prior to probing for loading controls.

Leucine Assay
4 x 105 Neuro-2A cells were seeded into 6 well plates and transfected 24
hours later with DNA plasmids. After 48 hours, cells were lysed, and leucine levels
were measured by performing a leucine assay following manufacturer instructions
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(Sigma-Aldrich, MAK003). 10 µL of lysate was added to a 96 well plate and diluted
to 50 µL using assay buffer. Next, 46 µL of assay buffer was added to each well,
along with 2 µL of BCAA enzyme mix and substrate mix for a final volume of 100
µL per well. Blanks were performed by mixing lysate with assay buffer and
substrate mix but omitting enzyme. The blank absorbances were subtracted from
lysate absorbances. A standard curve was generated with pure leucine. Readings
were acquired using a Synergy H1 Hybrid Reader. Each sample was measured in
duplicate.

bDNA FISH
bDNA FISH was performed using the Quantigene ViewRNA ISH Cell assay
according to the manufacturer’s instructions. Briefly, 4% paraformaldehyde fixed
tissue that was washed three times in PBS and permeabilized with Detergent
Solution QC followed by two rinses with PBS. Tissue was incubated in Protease
QS solution at 40°C for 60 minutes. Tissue sections was then incubated with Probe
Set Diluent QF with or without Slc7a5 probe set type 4 (Alexa Fluor 488) for 3 hr
at 40°C. Tissue was washed in 2 mL wash buffer for 5 min two times and then
incubated for 30 min at 40°C with PreAmplifier Mix and Amplifier Diluent QF prewarmed to 40°C. Samples were washed three times with 2 mL wash buffer for 5
min each wash. Next, tissue was incubated with 400 mL of the Label Probe Mix
diluted in Label Probe Diluent QF (pre-warmed to 40°C) for 30 min at 40°C.
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Samples were then washed three times in 2 mL wash buffer for 10 min,
counterstained, and mounted in ProLong Gold Antifade mounting reagent.

RT-PCR
OBs from mice were removed from ~P30 mice and subjected to TRIzol RNA
isolation according to the manufacturer’s protocol. Briefly, An OB was added to
~250 µL of TRIzol reagent and passed through a 22-gauge needle into 1.5 mL
reaction tubes. Samples were incubated at 4°C for 10 min. 50 µL of chloroform
was added to each tube, vortexed, and incubated for 10 min at 4°C. Samples were
centrifuged for 10 min at 12,000 x g at 4°C and the upper aqueous phase was
transferred to a fresh tube. 125 µL ice cold isopropanol was added to the aqueous
phase, samples incubated at 4°C for 10 min, and then centrifuged for 10 min at
12,000 x g at 4°C. Supernatant was discarded and RNA pellets washed in 250 µL
of 75% ethanol, vortexed, and centrifuged for 5 min at 7,500 x g. Samples were
washed a total of three times and the RNA pellet was air dried for 10 min and
resuspended in 50 µL of RNAase-free water prior to determining concentration and
purity. For reverse transcription polymerase chain reaction (RTPCR), RNA was
combined with deoxynucleotide triphosphates (dNTPs), random primers
(Invitrogen), and Rnase/Dnase-free H2O. Samples were heated for 5 min at 65°C
and then rapidly chilled. Dithiothreitol, Rnase out, and SuperScript III were then
added to each sample and reverse transcribed. cDNA was subjected to PCR using
primers to Slc7a5 and Platinum Taq polymerase.

52

Statistics
Data were graphed and analyzed with GraphPad Prism software (Version
8.2.0, GraphPad Software Inc.). Statistical significance was determined by
Student’s T-test (cell number analysis), one-way ANOVA (Western blots, ROI and
total number of crossings analysis) with multiple comparisons test, or two-way
ANOVA with Tukey’s multiple comparisons test (Sholl analysis). All experiments
were performed on 3- 8 mice per condition per timepoint.

Results
In vitro and in vivo genetic Slc7a5 manipulation.
Neuro-2a cells are a cancerous cell-line of neural origin that have high
transfection efficiency and are routinely used to study the mTOR pathway
(100,101). Neuro-2a cells were transfected with the human form of SLC7A5 under
the control of a CAG promoter. This plasmid increased SLC7A5 expression by
~100-fold as determined by western blot using an antibody that detects only the
human form of SLC7A5 (P<0.001) (Fig. 3.2.I A). Neuro-2a cells were also
transfected with a plasmid encoding mouse Slc7a5 fused to a myc-tag epitope
because no commercially available antibodies to Slc7a5 faithfully recognized
mouse Slc7a5 (data not shown). Slc7a5 was increased (P<0.0001) as determined
by western blot using an antibody to myc (Fig. 3.2.I B). In addition, a plasmid
encoding short hairpin (sh) RNA to Slc7a5 (shSlc7a5) was co-transfected with
mouse Slc7a5. Short hairpin RNA (shRNA) mediated knockdown of Slc7a5 was

53

validated by western blot with the antibody to myc and reduced Slc7a5 by ~71%
(P<0.0001) (Fig 3.2.I B). These results mirrored the effect of shSlc7a5 on mycSlc7a5 when compared with cells transfected with a control shRNA
and Slc7a5 (Fig. 3.2.II A). Moreover, shSlc7a5 reduced leucine import (Fig. 3.2.II
B).
P0 mouse SVZ NSCs were electroporated with red fluorescent protein
(RFP) and empty vector control, shSlc7a5, or SLC7A5 encoding plasmids. SVZ
NSCs give rise to neuroblasts that migrate along the RMS, enter into the OB
~7 days later, take an additional 7 days to extend dendrites into the GC layer, and
take ~16 more days to fully mature (Fig. 3.2.I C) (102). Brains were therefore
harvested and examined at P14 and P30. IHC with an antibody to human SLC7A5
revealed robust expression in RFP and SLC7A5 co-electroporated cells in the SVZ
(Fig. 3.2.I D,E). The number of SLC7A5 or shSlc7a5 cells in the SVZ did not
change in comparison to controls at P14 or P30 (Fig. 3.2.I F-L). Slc7a5 knockdown
was confirmed to persist in vivo at P30 (Fig. 3.2.III A). Slc7a5 protein is expressed
within the SVZ, RMS and OB (81). In situ hybridization (ISH) from the Allen
Institute confirmed Slc7a5 expression in OBs (Fig. 3.2.III B). Slc7a5 expression
was confirmed by reverse transcription-polymerase chain reaction (RT-PCR) (Fig.
3.2.III C). bDNA fluorescence in situ hybridization (FISH) demonstrated that
Slc7a5 mRNA was present in the GC layer (Fig. 3.2.III D,G). bDNA FISH was then
performed in RFP electroporated brains which confirmed expression within GCs
(Fig. 3.2.III E,F,H). OBs of the electroporated mice were next examined because
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neurons do not develop properly in Slc7a5 knockout mice and because patients
with SLC7A5 mutations have microcephaly (53,54).
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Figure 3.2.I In vitro and in vivo genetic Slc7a5 manipulation. A. Western blot
for SLC7A5 following control or SLC7A5 plasmid transfection of Neuro-2a cells
(N=6, 6). B. Western blot for myc from lysates of Neuro-2a cells transfected
with control, myc-Slc7a5 and control, or myc-Slc7a5 and Slc7a5 shRNA
plasmids (N=3, 3, 3). C. Schematic diagram representing a sagittal section of
the mouse brain. The diagram depicts electroporated (red) NSCs surrounding
the LVs that generate neuroblasts that migrate through the RMS and enter the
OB 7 days post-electroporation and become mature GCs 30 days postelectroporation. D,E. 20x image of RFP+ cells co-electroporated with SLC7A5
in the SVZ and stained for SLC7A5. Scalebar=50 μm. F-K. 5x images of P14
and P30 SVZs following P0 co-electroporation with RFP and control,
shSlc7a5, or SLC7A5 plasmids (P14 Control, N=6; shSlc7a5, N=6; or
SLC7A5, N=3) (P30 control, N=7; shSlc7a5, N=8; or SLC7A5, N=4).
Scalebar=100 μm. L. Quantification of F-K. LV=lateral ventricle, RMS=rostral
migratory stream, OB=olfactory bulb.
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Figure 3.2.II Confirmation of Slc7a5 shRNA specificity and leucine transport.
A. Western blot for myc from lysates of Neuro-2a cells transfected with control
shRNA, shSlc7a5, control shRNA with myc-Slc7a5, or shSlc7a5 and mycSlc7a5 plasmids (N=3, 3, 3, 3). Westerns were stripped and re-probed for total
Akt as a loading control. B. Leucine concentrations were measured in lysates
from A. and demonstrate a reduction in leucine concentration following Slc7a5
knockdown. (N=3, 3, 3, 3) *=P<0.05, ***=P<0.001. ****=P<0.0001.
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Figure 3.2.III Slc7a5 knockdown and OB GC expression. A. Quantification
of Slc7a5 staining at P30 in control (SLC7A5, empty vector, and RFP) (n=92)
or shSlc7a5 (SLC7A5, shSlc7a5, and RFP) electroporated cells (N=3, n=93).
B. In situ hybridization of Slc7a5 in a P56 sagittal brain section from the Allen
Mouse Brain Atlas. Image credit: Allen Institute. C. RT-PCR of mRNA from
P30 OB. D. bDNA FISH for Slc7a5 mRNA (green spots) OB. (N=3) E.
Overlap of RFP positive OB GCs (red) from P0 electroporations subjected to
bDNA FISH (F) for Slc7a5 mRNA (green) (N=3). Arrows point to Slc7a5
mRNA puncta staining in electroporated GC. G. Control label probe only for
bDNA FISH in a section from the same brain shown in D. H. Overlap of RFP
positive OB GCs (red) from P0 electroporations subjected to bDNA FISH (I)
for control label probe only in a section from the same brain as E-F. Arrows
indicate overlap of Slc7a5 in a GC. ****=P<0.0001.
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Slc7a5 is required for late phases of dendrite maturation.
Fourteen days after neuroblasts migrate away from the SVZ, they have
become immature neurons and have formed immature basal and apical dendrites
that extend into the GC layer of the OB (102,103). Dendrite arborization was
quantified in control, shSlc7a5 and SLC7A5 electroporated mice. P14 control GCs
exhibited a morphology similar to what has previously been shown in rats and more
recently in vivo in mice, having ~2.3 crossings within 50 μM of the cell soma,
characteristic of basal dendrites and a singular immature apical projecting dendrite
within the GC layer (Fig. 3.3.I A) (102,104). GC dendrite complexity was quantified
by tracing electroporated GCs, performing Sholl analysis, and calculating the total
number of dendrite crossings per GC. No significant changes to dendrite
complexity or total number of crossings were detected in shSlc7a5 or SLC7A5 GCs
compared with controls at P14 (Fig. 3.3.I A-E).
Additional phases of GC apical and basal dendrite growth and
maturation occur until GCs are 30 days old (102,103,105). In agreement, P30 GC
dendrite arbors appeared more complex than at P14 (Fig. 3.3.I A,F). There were
more proximal (basal) and distal (apical) dendrite crossings (Fig. 3.3.I D,I).
Moreover, the total number of dendrite crossings per GC increased from P14 to
P30 (P<0.001) (Fig. 3.3.I E,J). In contrast, Slc7a5 knockdown dendrite arbors
were critically reduced at P30 (Fig. 3.3.I G,I). Slc7a5 knockdown GCs had on
average ~25% fewer crossings within 50 μM and apical processes were truncated
(Fig. 3.3.I I). Moreover, Slc7a5 knockdown decreased the total number of dendrite
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crossings per neuron at P30 (P<0.0001) (Fig. 3.3.I J). During the same period,
SLC7A5 did not significantly change dendrite arborization further demonstrating
the specificity of this effect (Fig. 3.3.I H-J). Reduced dendrite complexity and total
number of crossings were verified with a second Slc7a5 shRNA (Fig. 3.3.II A,B).
Additionally, at P30 frequency histogram profiles highlighted that many RFP
positive cells in shSlc7a5 conditions had few to no dendrite processes and on
average, GCs had a smaller soma size (Fig. 3.3.II C,D). Taken together, these
results demonstrate that Slc7a5 is required for GCs to acquire and maintain mature
dendrite arbors and proper soma size.
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Figure 3.3.I Slc7a5 is required for late phases of dendrite maturation. AC. 20× images of P14 OB GCs from P0 electroporation of RFP and control,
shSlc7a5, or SLC7A5 plasmids. D. Sholl analysis of A-C (P14 Control N=6,
n=44; shSlc7a5 N=4, n=58; SLC7A5 N=3, n=23). E. Total number of
crossings per GC for A-C. F-H. 20× images of P30 GCs from P0
electroporation of RFP and control, shSlc7a5, or SLC7A5 plasmids. I.
Sholl analysis of F-H (P30 Control N=4, n=38; shSlc7a5 N=3, n=46;
SLC7A5 N=4, n=37). J. Total number of crossings per GC for F-H.
Scalebar=50 μm. ****=P<0.0001.
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Figure 3.3.II Slc7a5 knockdown GC dendrites, frequency histogram profile, and cell
size. A. Sholl analysis of P30 neurons following electroporation at P0 with RFP and a
second shRNA (shSlc7a5 2) to Slc7a5 or control plasmids (N=3, 3). B. Total number
of crossings per GC for A. (shSlc7a5 2, N=3, n=33 vs control, N=3, n=22). C. Frequency
histogram profile of total dendrite crossings per GC at P30 following electroporation at
P0 of control (N=4, n=38) or shSlc7a5 (N=3, n=46) plasmids. D. Cell size analysis of
GCs at P30 following electroporation at P0 of control (N=4, n=1326) or shSlc7a5
plasmids (N=3, n=450). ****=P<0.0001.
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Slc7a5 is required for developing GC survival.
Initially, GC proximal dendrites found in the GC layer receive GABAergic
input from surrounding GCs around P14 (103,105). By P30, dendrites reach the
external plexiform layer to receive glutamatergic input from tufted and mitral cells
that is critical for activity-dependent survival (102,103,105). Therefore, the extent
that Slc7a5 GCs survive with an immature (P14) or without a mature (P30) dendrite
arbor was determined. There was no difference in the number of RFP positive GCs
between control or shSlc7a5 conditions at P14 (Fig. 3.4.I A-C). This is not
surprising due to the absence of morphological defects by P14 following Slc7a5
knockdown. However, by P30 a robust phenotype manifested, with 70% fewer
GCs present after Slc7a5 knockdown compared with control (P<0.0001) (Fig. 3.4.I
D-F). By P70, the phenotype worsened, with almost no RFP labeled Slc7a5
knockdown GCs present in the OB (P<0.0001) (Fig. 3.4.I G-I). These findings were
also confirmed at P30 using a GFP plasmid to rule out the effect being caused by
RFP (P<0.01), as well as a second shRNA that targets Slc7a5 (P<0.001) (Fig.
3.4.II A-J). The results from these experiments demonstrate that Slc7a5 is required
for GC survival.
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Figure 3.4.I Slc7a5 is required for developing GC survival. A,B. 5× images of
P14 OBs from P0 electroporation of RFP and control or shSlc7a5 plasmids. C.
Relative number of RFP+ GCs at P14 for control or shSlc7a5 conditions. P14
control, N=6; shSlc7a5, N=6. D,E. 5x images of P30 OBs from P0
electroporation of RFP and control or shSlc7a5 plasmids. F. Relative number
of RFP+ GCs at P30 for control or shSlc7a5 conditions. P30 control, N=7;
shSlc7a5, N=8. G,H. 5x images of P70 OBs from P0 electroporation of RFP
and control or shSlc7a5 plasmids. I. Relative number of RFP+ GCs at P70 for
control or shSlc7a5 conditions (P70 control N=4; shSlc7a5 N=3).
Scalebar=100 µm. ****=P<0.0001.
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Figure 3.4.II Validation of GC death with an additional Slc7a5 shRNA.
A-D. 5x P30 Obs or SVZs from mice electroporated with GFP and control
or shSlc7a5 plasmids (Control, N=4; shSlc7a5, N=3). E. Quantification
of A-D. F-I. 5x P30 OBs or SVZs from mice electroporated with RFP and
control or a second alternative shRNA to Slc7a5 (Control N=3; shSlc7a5
N=3). J. Quantification of F-I. SVZ=Subventricular zone. **=P<0.01,
***=P<0.001. Scalebar=100 µm.
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Slc7a5 regulation of dendrite maturation depends on mTOR.
Since Slc7a5 can regulate the mTOR pathway and the mTOR pathway
regulates dendrite growth, it was tempting to speculate that the defects seen
following Slc7a5 knockdown could be caused by decreased mTOR pathway
activity (50,54,91,93,106). Ectopic Rheb binds to and activates mTORC1 in the
absence of leucine (107,108). It was hypothesized that if this occurred, overexpression of Rheb, a direct activator of mTORC1, might be able to overcome the
effect of Slc7a5 knockdown. To begin to address this hypothesis, littermates were
co-electroporated with RFP and control, Rheb, shSlc7a5, or shSlc7a5 and Rheb
plasmids. IHC was subsequently performed for pS6 at P30. As expected, Slc7a5
knockdown decreased pS6 by ~29% (P<0.0001) (Fig. 3.5.I A,B). This result
confirms that Slc7a5 regulates the mTOR pathway. Also as predicted, Rheb
littermates had ~26% more pS6 compared with control (P<0.0001) (Fig. 3.5.I A,B).
Notably, and as hypothesized, Slc7a5 knockdown GCs co-electroporated with
Rheb had pS6 levels completely rescued compared with control (Fig. 3.5.I A,B).
Since mTOR pathway activity was rescued in Slc7a5 knockdown GCs coelectroporated with Rheb, we wondered to what extent Rheb might also mitigate
dendrite defects in Slc7a5 knockdown GCs. First, dendrite morphology was
measured in control or Rheb electroporated GCs. Rheb by itself increased dendrite
complexity in agreement with increased pS6, similar to previous reports (P<0.001)
(Fig. 3.5.I C,E,G,H) (20,30). Consistent with Figure 3.3.I, Slc7a5 knockdown
decreased GC dendrite complexity compared with control (Fig. 3.5.I C,D,G,H). In
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contrast, shSlc7a5 and Rheb co-electroporated dendrite complexity was partially
rescued compared with Slc7a5 knockdown GCs (Fig. 3.5.I C,F,G). In addition to
Sholl analysis, the total number of crossings per GC was calculated. As expected,
shSlc7a5 GCs had ~53% fewer total crossings compared with controls, and this
decrease was rescued by Rheb (P<0.0001) (Fig. 3.5.I H). In shSlc7a5 OBs, there
was a 74% reduction in GCs compared with control OBs (P<0.0001) (Fig. 3.5.II).
However, Rheb co-electroporation increased the number of GCs to 220% of
shSlc7a5 alone (P<0.05) (Fig. 3.5.II). These results demonstrate that Slc7a5 is
required for mTORC1 pathway activity, dendrite maturation, and survival.
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Figure 3.5.I Slc7a5 regulation of dendrite maturation depends on mTOR.
A. Images of P30 GCs from RFP and control, shSlc7a5, Rheb, or shSlc7a5
with Rheb plasmids, stained for pS6. Scalebar=12.5 µm. B. Quantification
of pS6 staining intensity for A (Control N=3, n=39; shSlc7a5 N=5, n=33;
Rheb N=3, n=37; shSlc7a5 and Rheb N=5, n=60 C-F. 20x images of P30
GCs from P0 electroporation of RFP and control, shSlc7a5, Rheb, or
shSlc7a5 and Rheb plasmids. Scalebar=50 µm. G. Sholl analysis for C-F.
H. Total number of crossings per GC for C-F (Control N=3, n=23; shSlc7a5
N=4, n=35; Rheb N=5, n=32; shSlc7a5 and Rheb N=5, n=47).
****=P<0.0001.
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Figure 3.5.II ShSlc7a5 neuron survival following mTORC1
hyperactivation. Relative number of RFP+ GCs at P30 for control
(N=7), shSlc7a5 (N=8), Rheb (N=4), and shSlc7a5 and Rheb (N=5).
*=P<0.05. **=P<0.01. *****=P<0.0001.
Discussion
Mutations in Slc7a5 and components of the mTOR pathway result in
abnormal brain development and neurological manifestations. The evidence
presented here supports the hypothesis that Slc7a5 regulates mTOR pathway
activity and is required for neonatal OB GC dendrite maturation and survival. SVZ
NSCs were electroporated neonatally with Slc7a5 shRNA or SLC7A5 to attempt
to address the relative contribution of Slc7a5 to neural development. SVZ NSCs
generate neuroblasts that migrate through the RMS into the OB. The majority of
the neurons matures into inhibitory GCs of the GC layer and continues to mature
over a 30 day period (102,103,105). Slc7a5 knockdown did not change the number
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of cells in the SVZ at P14 or P30. SVZ NSCs rapidly dilute electroporated plasmids
into daughter cells, and therefore it could be argued that knockdown did not occur
in the time required to see an effect. However, knockdown in vitro occurred within
2 days, indicating that this is not a likely possibility. Although Slc7a5 knockdown
occurs rapidly, it could take a longer period of Slc7a5 depletion to exert an effect.
The fact that equal numbers of NSCs retain plasmid DNA and hence were
fluorescent at P14 and P30 would argue against time-dependent depletion being
critical for the survival of NSCs but could affect rates of proliferation or
differentiation.
Surprisingly, the quantity and morphology of Slc7a5 knockdown GCs did
not significantly differ from controls at P14. At this time of development, GC
dendrite arbors are immature and are able to respond electrophysiologically to
GABA but not glutamate (103,105). Robust dendrite arborization, spine formation
and electrophysiological responses of GCs to glutamate occur later, at ~28–
30 days, when dendrodendritic synapses are maturing in the external plexiform
layer (102,103,105). The results presented here support the notion of continued
GC dendrite growth into the external plexiform layer from P14 to P30.
We found that dendrites were critically malformed at P30. Mechanistically,
this was associated with reduced mTOR pathway activity. Slc7a5 knockdown
reduced leucine levels in Neuro-2a cells. Leucine binds to Sestrin2 to modulate
mTORC1 (88). The ratio of phospho-4E-BP to total 4E-BP, a measure of mTOR,
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is reduced in BBB Slc7a5 knockout mice (53). In comparison, Slc7a5 null embryos
had reduced pS6 potentially indicative of aberrant mTOR (54). Therefore, an
alternative interpretation of the current study is that there may be a loss in the
regulation of mTOR as opposed to strict loss of mTOR activation. Abnormal
dendrite arborization is a shared characteristic in a range of neurodevelopmental
disorders and these patients often present with neurological manifestations
including epilepsy that are indicative of hyper-connectivity. As an indication of an
active role of mTOR in the pathogenesis of epilepsy, mTORC1 inhibitors such as
the rapalogs decrease the frequency or severity of seizures in a disease with
elevated mTORC1 activity (109). In further support of the role that mTORC1 has
in dendrite morphology, ectopic Rheb expression increased dendrite arborization
similar to previous reports (20,30). Moreover, co-electroporation of Rheb partially
rescued the effect of Slc7a5 knockdown on survival. Ectopic Rheb binds to and
activates mTORC1 in the absence of leucine (107,108). It is therefore not
surprising that Rheb rescued the effect of Slc7a5 knockdown on dendrites.
Engineered deletion of mTOR exons 1–5 causes embryonic day 6.5–7.5
lethality (110). A mutagenic screen identified an intronic mutation leading to
reduced mTOR-prevented development of the telencephalon and led to death by
embryonic day 11 (111). The phenotype of mutant mTOR mirrors the phenotype
of a group of Slc7a5 knockout mice (54). This is similar to conditional mTOR
deletion using Nestin promoter-driven recombination (Cre), which causes
microcephaly and a thinning of the cortical plate by embryonic day 15 (39).
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Microcephaly in the mTOR conditional mice is correlated with reduced progenitor
proliferation and neurogenesis. However, mTOR is present within two complexes,
mTORC1 and mTORC2. Therefore, to what extent mTORC1, mTORC2, or both
are responsible for mTOR deletion phenotypes is not clear. Surprisingly, NestinCre deletion of rictor or raptor, which are the components of mTORC2 and
mTORC1 respectively, phenocopy Nestin-Cre deletion of mTOR (112,113).
Conditional raptor deletion also reduces progenitor proliferation and dendrite
growth of neurons, and induces robust apoptosis within cortical plate neurons
(113). However, these mice also have robust changes in gliogenesis. Nestin-Cre
rictor deletion similarly produces neurons with reduced dendrite arbors (112).
Thus, both mTORC1 and mTORC2 appear to be required for proper dendrite
morphology. Perhaps, more pertinent to this paper is the observation that
mTORC1 activity is high within the SVZ-RMS-OB axis, including in OB GCs where
translation becomes highly selective (44). mTORC1 knockdown in NSCs prevents
neuronal differentiation and provides evidence of the importance of mTORC1
regulation in neural differentiation (114). Indeed, rictor, raptor, and mTOR
knockdown as well as mTOR or raptor deletion by neonatal electroporation of SVZ
NSCs reduces OB GC mTORC1 activity and dendrite growth (115). These results
are consistent with previous observations that removal of negative regulators of
mTOR, such as TSC1/2, increase dendrite growth (42). Taken together, the loss
of Slc7a5 resulting in reduced or abnormal mTOR activity is consistent with current
models of how mTORC1 regulates OB GC maturation.
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A limitation of this study is that although Slc7a5 transports leucine,
numerous other amino acids, dopamine, and thyroid hormones (83–85,116,117).
Although the current study demonstrates that Slc7a5 is required for leucine
transport, it does not address whether other molecules are involved in the
requirement for Slc7a5 or whether compensatory changes may contribute to our
findings and further experimentation is required in future studies. A major question
that arises from these studies is why certain cells do not require Slc7a5, although
the existence of other transporters and mechanisms of acquiring nutrients such as
autophagy or micropinocytosis are possible. In summary, the results of this study
highlight the existence of a transient and cell-specific requirement for Slc7a5 to
regulate the mTOR pathway and GC dendrite growth.
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CHAPTER IV
Granule cell defects in Tsc2NSC-/- mice
Abstract
Tuberous Sclerosis Complex (TSC) is a multisystem disorder that results in
disrupted brain development, including aberrations in neuron morphology and the
formation of cortical tubers that are linked to cognitive defects and seizures.
Megalencephaly also frequently occurs from unchecked anabolic growth. TSC is
caused by a single inactivating gene mutation in TSC1 or TSC2, which takes away
the “brakes” on the pro-anabolic kinase mTORC1 and results in its upregulation.
Current treatments for TSC solely focus on symptom alleviation, such as surgery
to remove growths/tubers, anti-seizure drugs, and mTOR inhibitors. While helpful,
these treatments do not address many underlying neurological manifestations
associated with TSC patients. As seizure onset often occurs during the first year,
and early onset seizures are linked to cognitive defects, earlier proactive treatment
may alleviate cognitive symptoms of TSC. Uncovering underlying mechanisms in
which TSC results in altered brain development could lead to new avenues of
treatment, not only for TSC patients but also for other mTORopathies such as
Autism Spectrum Disorder and epilepsy. Utilizing Cre-lox technology, we use two
different models to investigate neurological defects following global and regionspecific Tsc2 deletion. First, we generated an inducible neural stem cell specific
Tsc2 knockout mouse, which underwent widespread recombination following
intraperitoneal injection with tamoxifen. To birthdate neurons and study region-
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specific effects of Tsc2 inactivation in the olfactory bulb, we also delivered DNA
plasmids encoding GFP and Cre recombinase into NSCs of the lateral ventricles
via neonatal electroporation into Tsc2fl/fl mice. Following Tsc2 inactivation,
olfactory bulb granule cells were found to have increased soma size and more
complex dendrite arborization. These findings demonstrate that our mouse model
exhibits a consistent TSC phenotype similar to patients and serves as an excellent
model to study mechanisms of altered neuron development.
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Introduction
Tuberous Sclerosis Complex (TSC) is a multisystem disorder that effects
~1:8000 people, with as many as 50% of TSC patients having intellectual
disabilities and ~40% being on the autism spectrum (118–120). The vast majority
also suffer from seizures that are detrimental to brain development. Cognitive and
behavioral issues as well as seizures manifest in TSC partly due to altered cortical
neuron connectivity and the formation of cortical tubers. Cortical tubers consist of
mislaminated dysmorphic/giant neurons in the cortex (120,121). TSC patients also
commonly develop growths in the LV that can cause hydrocephalus due to
pressure buildup (122,123). TSC was first described by Désiré-Magloire
Bourneville in 1880 as Bourneville disease following an autopsy on a young female
with intellectual disabilities that suffered from seizures (124). He discovered that
she had lesions in multiple regions in her body as well as cortical tubers, which he
attributed as the potential cause of the neurological issues. Our knowledge of TSC
and how to treat it has grown substantially since this time, with most current
therapeutic intervention involving mTOR inhibitors (i.e. rapamycin). While helpful,
earlier more effective treatment options are essential to improve patient quality of
life.
TSC is a genetic disorder caused by an inactivating mutation in TSC1 or
TSC2, which encodes for Hamartin (TSC1) and Tuberin (TSC2). These proteins
form a GTPase activating protein complex that inhibits mTORC1 by activating
Rheb GTPase activity (38,125,126). mTORC1 is a protein kinase which drives
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mRNA translation and cellular growth while inhibiting certain catabolic functions
(127). Typically patients have one mutant allele that is either inherited from one
parent (one-third of patients) or occurs sporadically (two-thirds of patients) in either
germline or somatic cells (128). This results in a loss of heterozygosity, and
explains the somatic mosaicism found in patients, with a subset of cells exhibiting
TSC1/2 inactivation (129,130). TSC1/2 inactivation results in upregulated
mTORC1 activity, classifying TSC as a mTORopathy.
Since TSC is caused by a single gene mutation, Tsc1/2 transgenic mice
have been a valuable tool in TSC research as well as a model for neuron
development. Tsc1/2 homozygous mutant mice are embryonic lethal; thus the use
of conditional knockouts is required (131,132). There are various conditional Tsc1
knockout mouse models that exhibit defective brain development and seizures.
Many of these models utilize Cre-recombinase technology to induce targeted
deletion of TSC. Previous studies have utilized transgenic Tsc1 mice expressing
Cre under the control of neural stem cell/progenitor-specific promoters including
GFAP, Nestin, and Emx1. These conditional Tsc1 knockout mice exhibited
decreased survival, NSC differentiation and cell fate defects, as well as neuron
cytomegaly, ectopic migration, and seizures (133–136). It is important to note that
while GFAP was solely considered an astrocyte marker, it is now widely known to
target NSCs as well. Tsc1 deletion in neurons have also been explored using
CamK2a and Synapsin Cre promoters, and resulted in similar developmental
defects such as altered neuron morphology, ectopic migration, decreased survival,
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and seizures (137–139). Tsc2 studies have used GFAP-Cre Tsc2 mice and also
documented similar developmental defects to Tsc1 knockout models (140,141).
Taken together, these models demonstrate that Tsc1/2 removal in NSCs,
neurons, or astrocytes result in various brain development defects that partially
phenocopy defects seen in patients. While much has been learned about
neurogenesis using these models, further research is needed. For one, many
previous studies have used knockout models that target Tsc1 as opposed to Tsc2,
despite Tsc2 mutations resulting in a more severe phenotype (128,142,143). The
difference in severity is likely due to the distinct roles of TSC1/2. TSC2 encodes
for the GAP domain, which regulates Rheb GTPase activation, whereas TSC1
provides complex stabilization (126). Additionally, many models do not utilize a
Cre activated fluorescent transgene, such as tdTOMATO, to confirm that any
changes in specific cells are an autonomous effect. This is an important distinction
as seizures frequently occur in the TSC phenotype and this can result in secondary
effects on neurons.
We propose to generate a NSC conditional Tsc2 knockout mouse colony
by crossing Tsc2fl/fl and Nestin-CreERT2 tdTOMATOMut/Mut mice into homozygosity.
The Tsc2fl/fl mice contain LoxP sites flanking exons 2-4 of the Tsc2 gene (144) .
Excision of Tsc2 at these sites prevents Tsc2 (tuberin) from forming a complex
with Tsc1 (hamartin) and results in Tsc2 (tuberin) degradation via ubiquitination
(145,146). Nestin-CreERT2 tdTOMATOMut/Mut mice express a fusion protein of Cre
recombinase with the modified estrogen receptor (ERT2) that is activated by
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tamoxifen (TX) and results in Tsc2 deletion. Expression of CreERT2 is driven by
the Nestin promoter, which results in specific Tsc2 deletion in neural
stem/progenitor cells. The tdTOMATO resides after a LoxP floxed STOP
sequence. Thus, tdTOMATO allows for the visualization of cells that have
underwent recombination, validating both CreERT2 activation while providing a
built-in control to confirm specificity of Nestin-CreERT2 activation. As highlighted
previously, tdTOMATO fluorescence also provides confirmation that analyzed cells
have underwent recombination. The resulting progeny will be Tsc2fl/fl; NestinCreERT2; tdTOMATOMut/Mut mice (referred herein as Tsc2NSC-/- mice). To induce
widespread TSC2 inactivation, mice will be injected with TX neonatally. This will
allow for precise examination and exploration of in vivo OB GC development to
model defects. This Tsc2NSC-/- model will allow for novel insights into mechanisms
that result in the TSC/mTORopathy phenotype.
Although this model will serve as a powerful tool to study TSC, there are
limitations relying solely on TX-CreERT2 mediated recombination to study neuron
development TSC. We lack the ability to birthdate recombined cells labeled from
neonatal TX administration, and there is a wide range of age heterogeneity in the
OB due to ongoing GC neurogenesis. Since certain analysis depend on the age of
the GCs, we can utilize the previously described electroporation technique from
Chapters I-III to neonatally electroporate CAG-Cre and CAG-GFP DNA plasmids
into the LV to target neuron producing NSCs. This method will also result in Tsc2
excision and inactivation, while also transiently labelling a subset of cells with GFP.
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We can then accurately analyze GCs with similar birthdates as the GFP plasmid
dilutes out. Previous studies have successfully validated electroporations on Tsc1
knockout mice, and our laboratory has previously published using the
electroporation technique (20,42,48,51). Electroporations also achieve Tsc1/2
inactivation in a more similar manner to inactivation exhibited in TSC patients, with
a small subset of NSC/progenitors undergoing Tsc1/2 inactivation and giving rise
to cells that inherit those mutations.
The dual approaches of using a TX-inducible Nestin-CreERT2 mouse colony
or introducing CAG-Cre via plasmid electroporation to induce Tsc2 inactivation in
Tsc2fl/fl mice allows for examination of both global and localized effects of Tsc2
deletion during neuron development. The experiments presented here validate the
Tsc2NSC-/- mouse model using both strategies of Tsc2 excision and explore Tsc2
null OB GC defects.

Methods
Slice preparation and immunohistochemistry
Performed as described in chapter I using primary antibody pS6 (rabbit antipS6; 1:1000; Cell Signaling Technology; Ser 240/244, 61H9, #4838). Images were
acquired on a spectral confocal microscope (Leica SPE) with a 20× dry objective
(N.A. 0.75). Low-magnification images were acquired with a 5× dry (N.A. 0.15)
objective.
Image analysis
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20× images were uploaded and analyzed using Fiji (ImageJ 1.5g). Sholl,
soma size, and cell # were performed as described previously.

Tamoxifen Injections
Newborn pups were injected intraperitoneally with 50 µg/g TX, once at P0
and once at P1, and sacrificed at indicated ages. Mice were routinely monitored
for adverse effects.

Genotyping PCR
DNA samples were incubated in 75 μL 50 mM NaOH buffer at 50 °C for 90120 minutes. Following incubation, an equal volume of 100 mM Tris-HCl was
added to samples. DNA concentration was calculated using a nanospectrometer.
Samples were stored at −20 °C, and PCR was performed using platinum TAQ
following manufacturer instructions (Thermofisher Scientific; 10966018).

Neonatal electroporation
Electroporations were performed as previously described in chapter III
using a CAG-Cre and CAG-GFP plasmid at ~1.0-2.0 µg/µL.
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Results
The TSC-mTOR pathway.
The TSC1/2 (Harmartin-Tuberin) complex reduces mTORC1 activity in
response to starvation signals that activate AMPK, which then phosphorylates and
activates TSC1/2. TSC1/2 then inhibits the mTOR activator Rheb. When growth
signals are present, TSC1/2 is inactive and Rheb activates mTORC1 at the
lysosome (Fig. 4.1A). Inactivating mutations in TSC1/2 lead to unchecked mTOR
activity that is no longer sensitive to growth and starvation signals (Fig. 4.1B).

Figure 4.1 The TSC-mTOR pathway. A. Canonical TSCmTOR pathway. B. TSC-mTOR pathway following TSC1/2
inactivation.
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Tsc2fl/fl tdTOMATOMut/Mut Nestin-CreERT2 mouse colony generation.
Tsc2fl/fl mice were first crossed with Nestin-CreERT2 × tdTOMATOMut/Mut
mice and crossed into homozygosity (Fig. 4.2A,B). All three transgenes were
successfully incorporated in the expected mendelian ratios and validated by PCR
(Fig. 4.2B). As described previously, NSCs produce progenitor cells that migrate
through the RMS into the OB, where they then mature into functional GCs (Fig.
4.2C). TX injection was administered two times neonatally, which resulted in robust
recombination by P30 as demonstrated by red NSCs in the SVZ as well as red
neurons in the OB (Fig. 4.2D-E). Recombined cell types were confirmed by the
neuron marker NeuN, the NSC marker nestin, and the NSC/astrocyte marker
GFAP. This confirms the incorporated transgenes are working correctly, with TX
injection resulting in predictable patterning of recombination in nestin positive
NSCs and the neuron progeny.

83

Figure 4.2 Tsc2fl/fl tdTOMATOMut/Mut Nestin-CreERT2 mouse
colony generation. A. Image of Tsc2NSC-/- mouse. B. PCR
validation of indicated genotypes. C. Schematic diagram of a P30
sagittal mouse brain demonstrating the migration pattern from the
LV to the OB through the RMS. D. P30 tdTOMATO positive NeuN
positive OB GCs following neonatal TX injections with NeuN
(green) IHC. E. P30 tdTOMATO positive neural stem cells in the
SVZ with nestin (green) and GFAP (blue) IHC.
IHC=Immunohistochemistry. LV=Lateral Ventricle. OB=Olfactory
bulb. RMS=Rostral Migratory Stream. GCL=Granule cell layer.
EPL=External plexiform layer. SVZ=Subventricular zone.
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mTORC1 activity upregulation in Tsc2 null OB GCs.
Next, we wanted to confirm that mTORC1 activity was upregulated following
Tsc2 removal. As demonstrated in Chapter III, neuron development involves
changes in pS6 levels depending on the stage of growth. Additionally, GCs are
continuously being produced throughout neonatal development. To compare
mTORC1 activity more accurately between conditions, we shifted from TX injection
to CAG-Cre and CAG-GFP neonatal electroporation of Tsc2fl/fl mice to study TSC2
excision in OB GCs (Fig. 4.3A,B). Electroporations allowed us to examine GFP
and tdTOMATO co-labeled GCs only, which successfully underwent Cre mediated
recombination (red) and share a similar birthdate (green). Controls were littermates
electroporated with an empty vector plasmid instead of Cre, thereby leaving the
Tsc2 gene fully functional. Cre electroporations also result in many neighboring
nonelectroporated GCs that have full Tsc2 functionality. This allows for another
built in control where we can compare IHC intensity of Tsc2 null GCs with
surrounding nonelectroporated cells. To examine mTORC1 levels, we performed
pS6 Ser240/244 IHC at P14 and P30. pS6 was ~45% higher in Tsc2 null neurons
at P14 compared to nonelectroporated controls (P<0.0001) (Fig. 4.3C-E).
Interestingly, by P30 the pS6 expression increase in Tsc2 null GCs decreased to
just ~7% compared to both nonelectroporated controls and GFP empty vector
electroporated controls (P<0.05) (Fig. 4.3F).
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Figure 4.3 mTORC1 activity upregulation in Tsc2 null OB GCs. A.
P14 tdTOMATO expression in the OB 14 days following neonatal
Cre and GFP electroporations. B. P14 GCs in the GCL
demonstrating plasmid GFP expression, tdTOMATO, and pS6 IHC.
C-E. PS6 upregulation in OB GCs by P14 following Tsc2 removal.
Arrows indicating upregulated pS6 in recombined GCs (P14 Control,
N=4, n=82; P14 +Cre N=4, n=82). F. P30 pS6 intensity analysis (P30
N=4,
n=34).
Control,
N=4,
n=41;
P30
Tsc2fl/fl,
IHC=Immunohistochemistry. GC(L)=Granule Cell (Layer). *=P<0.05.
****=P<0.0001.
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Morphological changes in Tsc2 null GCs.
To assess the effect of Tsc2 inactivation on developing GCs, I next
performed morphological analysis at P30 following neonatal electroporation of
GFP and Cre into Tsc2fl/fl mice (Fig. 4.4A,B). Littermate controls were
electroporated with an empty vector plasmid in place of Cre. Consistent with what
was expected based on previous studies, P30 Tsc2 null GC soma size increased
by ~25% (P<0.0001), and basal dendrite complexity increased by ~71% within 50
microns of the soma (P<0.0001) (Fig. 4.4C,D). To confirm this was not a
nonspecific Cre plasmid effect, the experiment was repeated using Cre
electroporated Tsc2fl/wt mice as a control. Tsc2fl/wt GCs still have one functional
allele following Cre electroporation, mitigating any defects. Consistent with our
previous finding, Cre electroporated Tsc2fl/fl GCs underwent a 30% increase in
soma size compared to Cre electroporated Tsc2fl/wt GCs (P<0.0001) (Fig. 4.4E).
Taken together, TSC2 inactivation in Nestin positive cells during brain
development recapitulates many major hallmarks of patients, including
upregulated mTOR activity and altered neuron development. Both TX and Cre
electroporated methods of Tsc2 excision were validated. These findings set the
foundation in which future work using this colony will allow for robust investigation
of neuron development and the underlying mechanisms of neurodevelopmental
disorders.
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Figure 4.4 Morphological changes in Tsc2 null GCs. A. Representative
image of a P30 control empty vector and GFP electroporated OB GC. B.
Representative image of a P30 Cre and GFP electroporated OB GC. C.
P30 soma size analysis (P30 Control, N=4, n=207; P30 +Cre, N=4, n=116).
D. P30 Sholl analysis (P30 Control, N=3, n=23; P30 +Cre, N=4, n=30). E.
P21 soma size analysis comparing Cre electroporated Tsc2fl/wt mice versus
Tsc2fl/fl mice (P21 Tsc2fl/wt, N=2, n=365; P30 Tsc2fl/fl, N=4, n=802).
IHC=Immunohistochemistry. ****=P<0.0001.

88

Discussion
The data presented here provides evidence that the generated Tsc2NSC/- mouse

line is an excellent model to study both neuron development and TSC

associated brain defects. This Tsc2NSC-/- model faithfully recapitulates key
hallmarks found in other TSC mouse models (42,133–141). Our results are also
consistent with previous studies, which demonstrate that mTORC1 upregulation
via Rheb overexpression results in neuron cytomegaly, dendrite hypertrophy, and
ectopic migration (20,30).
We found that changes in pS6 expression were more pronounced at P14
than P30 in Tsc2 null GCs. The fact that Tsc2 inactivation appears to upregulate
mTORC1 activity more robustly at earlier stages of neuron development indicates
that immature neurons/neuroblasts may be more sensitive to Tsc2 alterations. A
previous study investigating Tsc1 inactivation in NSCs/ astrocytes in mice did not
find changes in radial glia proliferation or cell number; however, neurons exhibited
an enlarged soma, upregulated mTOR activity, and ectopic migration (140). Taken
together, this suggests that the neuroblast/immature neuron stage of neurogenesis
is a particularly critical window in which altered mTOR activity is detrimental.
Other studies have focused on the effect of Tsc1 inactivation in post-mitotic
cortical neurons using Camk2a-Cre Tsc1 mice, which exhibit seizure activity by 5
weeks of age (139). The authors of the study postulated that the observed
hyperexcitability resulted from increased mTOR-dependent autophagy (139). They
found increased P62 and pUlk1 Ser757 expression in various brain regions
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of Tsc1 transgenic mice. P62 is an autophagosome cargo protein that
accumulates if autophagic processes are low (147). pUlk1 Ser757 is an mTORC1
substrate and results in Ulk1 inhibition (69). Therefore, TSC1/2 inactivation may
affect neuron development by decreasing autophagy. This in turn would disrupt
synaptic pruning—a period of removal and refinement of synaptic connections
following vast neuron outgrowth (43,148,149). Another study utilized Synapsin-Cre
Tsc1 transgenic mice to excise Tsc1 in neurons and found similar issues such as
decreased survival and seizures (137). Taken together, Tsc1/2 inactivating
mutations is detrimental to brain development and function in multiple cell types.
Future experiments using this Tsc2fl/fl colony should include performing in
utero electroporations of Cre plasmid to examine if cortical tubers form. Excision
of Tsc2 mediated by the TX-inducible CreERT2 recombinase is too widespread and
ineffective at inducing the formation of cortical tubers and/or nodules in the LV that
typically result from Tsc1/2 inactivation in a subset of cells. Methods utilizing
plasmid

introduction

by

neonatal

or in

utero electroporation

to

remove Tsc1/2 more faithfully recapitulate cellular heterogeneity and mosaic
patterning that occurs in TSC patients. In utero electroporations involve the
injection of plasmid DNA into the LV when cortical neurons are being generated.
The nature of in utero electroporation facilitates inactivation in a subset of cells
much like what occurs in patients with cortical tubers. As TSC patients start with
one working allele, somatic mosaicism develops with a second hit mutation
occurring in a progenitor/NSC, leading to a subset of cells with biallelic TSC1/2
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inactivation (150,151). Thus, Cre-mediated recombination introduced via
electroporation more accurately models TSC1/2 recombination in patients
compared to TX- CreERT2 mediated Tsc1/2 inactivation in mice. Finally, seizure
activity should be monitored following neonatal and in utero electroporations.
Global recombination of Tsc2 by Nestin-CreERT2 should be used as a
supplementary technique to examine the brain defects in Tsc2NSC-/- mice. The use
of two different methods of Cre mediated Tsc2 inactivation in this colony provides
the framework for the future expansion in the existing body of knowledge for
neuron development and TSC.
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CHAPTER V
Conclusion
Summary, Significance, and Future Directions
The findings presented here highlight the intricacies of neuron development
and how alterations in neuronal machinery result in neurodevelopmental defects.
Through advanced in vivo genetic manipulation using in utero and neonatal
electroporations, I provide mechanistic insight into how Slc7a5 and Ulk1 play a role
in neuron development and survival (51). Alternation to either Slc7a5 or Ulk1
expression was found to result in defective neuron development. Both were found
to be directly involved with mTORC1 during development, with Slc7a5 regulating
mTORC1 activity in OB GCs and Ulk1 being phosphorylated by mTORC1 in
cortical pyramidal neurons.
The potential clinical significance of SLC7A5 is highlighted in the fact that
Slc7a5 rescued Rheb overexpression mediated morphological changes such as
increased mTORC1 activity and dendrite hypertrophy (51). This demonstrates
SLC7A5 may be able to reduce mTOR activity and rescue neuron morphology in
TSC patients. The activation of mTORC1 relies on the presence of amino acids
and growth factors. Growth factors induce mTORC1 activity through the inhibition
of TSC1/2, while amino acids activate mTORC1 through an independent Sestrin2Rag GTPase pathway (94,152). Thus, while TSC1/2 null cells are no longer
sensitive to the absence or presence of growth factors, perhaps mTORC1
upregulation can be controlled through the reduction of SLC7A5 transport of amino
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acids into the cell. Interestingly, an abnormal cell type found in the cortex of TSC
patients, known as balloon cells, have upregulated SLC7A5 expression (55). As
SLC7A5 mutations have also been found to cause autism spectrum disorder, the
continued investigation of how SLC7A5 is involved with neuron development is
essential to move the field forward, with the hope of uncovering more effective
therapeutic strategies and targets (53).
Additionally, altered autophagy has been found in TSC mouse models and
autism spectrum disorder patients, highlighting the potential importance of Ulk1
regulation in neuron development (43,139). Interestingly, studies demonstrate that
autophagy is required to support upregulated mTOR in Tsc1/2 null cells, and that
inactivation of the autophagy gene Fip200 rescued the TSC phenotype (153). Our
data suggests that Ulk1 is robustly inhibited by mTORC1 in developing neurons.
This would suggest that ULK1 is likely involved with autophagic dysregulation in
TSC patients. Further work must be conducted to explore the link between
mTORC1 and ULK1 in patients with mutations resulting in increased mTORC1
activity. If the role of autophagy and ULK1 can be confirmed, it can potentially be
exploited as another potential therapeutic target.
The continued exploration of neuron development regulators and their role
in neurodevelopmental disorders is of vital importance for the continued expansion
of our body of knowledge. For the more we uncover about the inner workings of
the brain, the greater we will be able to meet patient needs.
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